




# Saturated Five-Membered Thiazolidines and Their Derivatives: From Synthesis to Biological Applications

Nusrat Sahiba<sup>1</sup> · Ayushi Sethiya<sup>1</sup> · Jay Soni<sup>1</sup> · Dinesh K. Agarwal<sup>2</sup> · Shikha Agarwal<sup>1</sup> 

Received: 1 June 2019 / Accepted: 7 March 2020 / Published online: 23 March 2020  
© Springer Nature Switzerland AG 2020

## Abstract

In past decades, interdisciplinary research has been of great interest for scholars. Thiazolidine motifs behave as a bridge between organic synthesis and medicinal chemistry and compel researchers to explore new drug candidates. Thiazolidine motifs are very intriguing heterocyclic five-membered moieties present in diverse natural and bioactive compounds having sulfur at the first position and nitrogen at the third position. The presence of sulfur enhances their pharmacological properties, and, therefore, they are used as vehicles in the synthesis of valuable organic combinations. They show varied biological properties viz. anticancer, anticonvulsant, antimicrobial, anti-inflammatory, neuroprotective, antioxidant activity and so on. This diversity in the biological response makes it a highly prized moiety. Based on literature studies, various synthetic approaches like multicomponent reaction, click reaction, nano-catalysis and green chemistry have been employed to improve their selectivity, purity, product yield and pharmacokinetic activity. In this review article, we have summarized systematic approaches for the synthesis of thiazolidine and its derivatives, along with their pharmacological activity, including advantages of green synthesis, atom economy, cleaner reaction profile and catalyst recovery which will help scientists to probe and stimulate the study of these scaffolds.

---

✉ Shikha Agarwal  
shikha\_urj@yahoo.com

Nusrat Sahiba  
sahibanusrat786@gmail.com

<sup>1</sup> Department of Chemistry, Synthetic Organic Chemistry Laboratory, MLSU, Udaipur 313001, India

<sup>2</sup> Department of Pharmacy, B. N. University, MLSU, Udaipur 313001, India

## Article Highlights

- **Thiazolidine derivatives have diverse therapeutic and pharmaceutical activity and are used in probe design.**
- **The novel synthesis of thiazolidine derivatives using various agents is discussed with respect to yield, purity, selectivity and pharmacokinetic activity.**
- **The accessible clinical applications in various biological targets are critically reviewed.**
- **These data provide useful information for designing next-generation drug candidates.**
- **Developing multifunctional drugs and improving their activity should be a focus of research.**

**Keywords** Thiazolidine · Thiazolidinone · Synthesis · Biological profile · Anticancer · Antimicrobial · Antitubercular activity

## Abbreviations

iNOS	Inducible nitric oxide synthase
MWI	Microwave irradiation
DMF	Dimethylformamide
TGA	Thioglycolic acid
p-TSA	<i>p</i> -Toluenesulfonic acid
DROC	Domino ring-opening cyclization
TBAHS	Tetrabutylammonium hydrogen sulfate
DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
ATAs	$\beta$ -Amidothioamides
DDs	1,2-Diaza-1,3-dienes
THF	Tetrahydrofuran
HT29	Human colon cancer cell line
MCF-7	Human breast cancer cell line
EWG	Electron-withdrawing group
EDG	Electron-donating group
APTES	Aminopropyltriethoxysilane
MCR	Multicomponent reaction
MNP	Magnetic nanoparticle
IL	Ionic liquid
DDC	Dicarbethoxydihydrocollidine
EDC-HCl	<i>N</i> -Ethyl- <i>N'</i> -(3-dimethylaminopropyl)carbodiimide hydrochloride
DMSO	Dimethyl sulfoxide
DES	Deep eutectic solvent
APS	Ammonium persulfate
FG	Functional group
o-DCB	Ortho-dichlorobenzene
SET	Single-electron transfer mechanism
DAAD	Dialkylacetylene dicarboxylate


EC50	Half maximal effective concentration
Thfg	Tetrahydrofuranyl glycine
MIC	Minimal inhibitory concentration
ee	Enantiomeric excess
MCF10A	Normal breast epithelial cells
TZD	Thiazolidine-2,4-dione
T3SS	Type III secretion system
Xoo	<i>Xanthomonas oryzae</i> pv. <i>oryzae</i>
DFT	Density functional theory
HOBt	1-Hydroxybenzotriazole
KSCN	Potassium thiocyanate
HepG2	Hepatocellular carcinoma
KB	Epidermoid carcinoma
LLC	Lewis lung carcinoma
A549	Human lung cancer cell line
DU145	Human prostate cancer cell line
HeLa	Human cervical cell line
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay
GAC	Glutaminase C
GAC	Glutaminase B
SI	Safety index
DPPH	2,2-Diphenyl-1-picrylhydrazyl
ABTS	2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid
PDF	Peptide deformylase
ATCC	American Type Culture Collection
SAR	Structure–activity relationship
CAIX	Carbonic anhydrase IX
SRB	Sulforhodamine B
MFC	Minimum fungicidal concentration
GMK	Green monkey kidney
CNS	Central nervous system
IC50	Half maximal inhibitory concentration
COX-2	Cyclooxygenase-2
G2	Gap 2 phase
M phase	Mitosis phase
PBMC	Human peripheral blood mononuclear cell
GI	Glycemic index
PK-LDH	Pyruvate kinase lactate dehydrogenase coupled assay
PKM2	Pyruvate kinase M2 isoform
DSF	Differential scanning fluorimetry assay
AO-EB	Acridine orange-ethidium bromide
GAB	Glutaminase B
DMAP	4-Dimethylaminopyridine
TZD	Thiazolidinedione
CDI	1,1'-carbonyldiimidazole
COPD	Chronic obstructive pulmonary disease

DIPEA	<i>N,N</i> -diisopropylethylamine
PDE4	Phosphodiesterase 4
CQ	Chloroquine
CQR	Chloroquine-resistant
ADME	Absorption, distribution, metabolism, excretion
EMT	Emetine
AR	Aldose reductase
HIV	Human immunodeficiency virus
C/EBP $\alpha$	Enhancer-binding protein alpha
PPAR $\gamma$	Peroxisome proliferative activator receptor gamma
SMI	Schizont maturation inhibition
OGTT	Oral glucose tolerance test
PTP1B	Protein-tyrosine phosphatase 1B
CUPRAC	Cupric ion reducing method
LBD	Ligand-binding domain
EDTA	Ethylenediaminetetraacetate
HBD	Hydrogen-binding domain
MES	Maximal electroshock seizure
PMD	Pentamidine
OUA	Ouabain
BD	Bipolar disorder
Se-PTC	Se-phenyl-thiazolidine-4-carboselenoate
CBTMT	( <i>Z</i> )-5-(4-Chlorobenzylidene)-3-(benzo[d]thiazol-2-yl)-2-(4-methoxyphenyl)thiazolidine-4-one
MBTMT	( <i>Z</i> )-5-(4-Methoxybenzylidene)-3-(benzo[d]thiazol-2-yl)-2-(4-methoxyphenyl)thiazolidine-4-one
EIS	Electrochemical impedance spectroscopy
EAC	Ehrlich ascites carcinoma

## 1 Introduction

Heterocyclic composites are an important class of organic compounds possessing broad applications in various fields of science [1–7]. One of the most eminent heterocyclic motifs, thiazolidine, is a five-membered heterocycle system having the formula  $C_3H_7NS$  containing one nitrogen and one sulfur atom, and which exhibits notable medicinal and pharmaceutical properties. In the thiazolidine nucleus, a large number of substitutions are possible on 2, 4 and 5 positions responsible for enhancing the compound's pharmaceutical importance. Thiazolidine and its composites are key components of many natural products and drugs (Fig. 1), and are also present in many synthetic compounds such as anticancer [8–11], antimicrobial [12–14], anti-tumor [15, 16], antidiabetic [17], antiparasitic [18, 19], anti-inflammatory [20–22], antitubercular [23], antifungal [24], antiviral [25, 26], anti-HIV [27–29], cytotoxicity [30], antitrypanosomal [31], antinociceptive and anti-hypernociceptive compounds [32]. In addition, the use of thiazolidines as an inhibitor of tyrosyl-DNA






**Fig. 1** Some commercially available thiazolidine-based drugs


phosphodiesterase I [33] and influenza neuraminidase [34], pro-drugs for the treatment of cystinosis [35], radioprotective against  $\gamma$ -irradiation [36] and as S1P1 receptor agonists [37, 38] has also been reported. They are also used in peptide and protein modification [39], protein chemical synthesis [40], as activators to innate immunity [41] and also act as immunostimulating agents [42].

These derivatives are also involved in various syntheses as synthetic precursors, potential biomarkers for oxidative stress and formaldehyde exposure [43], heterogeneous catalysts [44, 45], free radicals, superoxide anion radical and hydroxyl radical scavengers [46–48], inducible nitric oxide synthase (iNOS) inhibitors [49], to construct non-fullerene small molecules [50] and on and on. Green chemistry was formulated in the 1990s and includes 12 principles. The green processes diminish the adverse effects of any chemical reaction by following certain criteria viz. catalyst- and solvent-free synthesis and designing of biodegradable and less toxic products with high efficiency. In this review article, we have compiled researches which step ahead toward green chemistry. In the past few years, divergent synthetic strategies [51] have been introduced aimed at efficient and green synthesis using inexpensive reactants, nontoxic solvents, reusable catalysts, nanoparticle-catalyzed synthesis and solvent-free synthesis with high yields using different techniques such as microwave irradiation (MWI), sonochemistry, surface chemistry and others (Fig. 2). Multicomponent reactions (MCRs) (Strecker, Ugi, Bucherer-Bergs, Biginelli) are excellent pathways for the synthesis of heterocycles [52] as they have all the features for ideal synthesis like simple procedure for generating complex hybrid molecules in fewer steps which possess excellent pharmaceutical activity with high atom economy and eco-friendliness [53, 54]. The notable features of thiazolidine scaffolds compel us to study the literature and outline the current status of thiazolidine, its derivatives and also their biological significance. Recently, Jain et al. [55] reviewed the biological activity of thiazolidinone derivatives from 2000 to 2011. In 2013, Jain and coauthors [56] reviewed the multifarious applications of various thiazolidine-2,4-dione derivatives. Nanjan et al. [57] reviewed the antidiabetic activity of thiazolidinone. But there is no detailed review of the synthesis and biological activity of

**Fig. 2** Different synthetic pathways for the thiazolidine motif



thiazolidines to date. So here, we have summarized a literature survey of different strategies developed for the synthesis of thiazolidines and their analogs, highlighting their activity and their use as starting materials in the synthesis of various heterocyclic systems with potent pharmaceutical properties during the period of 2014–2019,



**Fig. 3** Synthesis of secondary amines via three different pathways; (iii) represents the efficiency and diversity of MCRs. Modified from Ref. [61]




Fig. 4 Comparative study of various synthetic protocols [58–69]






Fig. 5 Comparative study of various synthetic protocols [77–86]



**Fig. 6** Comparative study of various synthetic protocols [87–97]

hoping to inspire new and even more creative approaches for researchers (Fig. 3). We have also included a comparative study of various synthetic protocols of thiazolidine derivatives with their advantages (+) and disadvantages (–) (Figs. 4, 5, 6, 7). In this review, an endeavor has been made to underline the recent issues in thiazolidine synthesis like environmental, health, cost and energy issues. By using truly greener pathways, we can overcome these factors for a promising future of thiazolidine derivatives.



**Fig. 7** Comparative study of various synthetic protocols [98–102]


## 2 Synthesis of Thiazolidine Derivatives


### 2.1 Acid-Catalyzed Synthesis

Shelke and his coworkers [58] described a simple, more proficient, less wasteful, cost-effective, one-pot mechanism for the formation of bioactive 2-((substituted)-2-chloroquinolin-3-yl)-3-((substituted) phenyl) thiazolidin-4-ones (**4**) from 2-chloroquinoline-3-carbaldehyde (**1**), aniline (**2**) and thioglycolic acid (TGA) (**3**) with  $\beta$ -cyclodextrin-SO<sub>3</sub>H catalyst (Scheme 1). The authors studied this procedure in different conditions like various solvents (isopropanol, methanol, acetic acid, toluene, ethanol and DMF) and varied catalysts (p-TSA, sulfamic acid, hydrochloric acid and sulfanilic acid). In this synthesis,  $\beta$ -cyclodextrin-SO<sub>3</sub>H was the most favorable with water as its heterogeneous biopolymer-based solid acid catalyst and was reusable without any vital changes. A safe and greener reaction pathway, low toxicity, high yield of product and easy isolation method were advantages of this protocol. The reaction mechanism is depicted in Scheme 2. The mechanism shows that  $\beta$ -cyclodextrin-SO<sub>3</sub>H might first activate the aldehyde by enhancing the electrophilic character of its carbonyl moiety which formed an imine intermediate and  $\beta$ -cyclodextrin-SO<sub>3</sub>H anion, and this anion further increased the nucleophilic character of thioglycolic acid which reacted with the imine intermediate and formed an adduct, which was further activated by  $\beta$ -cyclodextrin-SO<sub>3</sub>H anion, followed by ring closure and final dehydration, resulting in formation of novel products.


Bhattacharyya and coauthors [59] investigated an ingenious, catalytic, regio- and stereoselective methodology for the preparation of various 2-iminothiazolidines from racemic and non-racemic activated aziridines and substituted isothiocyanates using Lewis acid-catalyzed DROC. A general mechanism for DROC-mediated synthesis explained that initially *N*-arylsulfonylaziridine, activated by the Lewis acid (BF<sub>3</sub>·OEt<sub>2</sub>) with TBAHS, gave an intermediate which was highly reactive and showed S<sub>N</sub>2-type ring-opening reaction with isothiocyanates to furnish a new intermediate with an inverted configuration. This intermediate underwent 5-exo-dig cyclization to afford 2-iminothiazolidine (**7**) derivatives, which have high yields and excellent enantioselectivity (Scheme 4). In this synthetic strategy, different stereoisomers under different conditions gave enantio- and diastereospecific products. Firstly, enantiopure (*R*)-2-phenyl-*N*-tosylaziridine (**R**)-**5a** reacted with phenyl isothiocyanates **6a**, using scandium(III) triflate as a catalyst in dichloromethane at 0 °C, to form (*S,Z*)-*N*,5-diphenyl-3-tosylthiazolidin-2-imine ((*S*)-**7a**) single regioisomer (52%) with low enantiomeric excess (34%) (Scheme 3). Various solvents, catalyst

**Scheme 1** Synthesis of 1-[(substituted)-2-chloroquinolin-3-yl]-3-[(substituted) phenyl] thiazolidin-4-one **4**






**Scheme 2** Possible mechanism for the synthesis of thiazolidinone derivative **4**. Modified from Ref. [58]



**Scheme 3** Synthesis of thiazolidine derivatives using domino ring-opening cyclization

and temperatures were applied to obtain the best reaction conditions. When the reaction was catalyzed by  $\text{BF}_3 \cdot \text{OEt}_2$  and TBAHS (tetrabutylammonium hydrogen sulfate) at  $-30^\circ\text{C}$ , high yields were obtained (97%) with excellent enantiospecificity (98% ee). The authors also studied the effect of different substituents on yield and stereoselectivity. This study continued in substituted (*R*)-2-phenyl-*N*-arylsulfonylaziridines and phenyl isothiocyanate under previous reaction conditions and formed corresponding 2-iminothiazolidines with good enantiomeric excess. When 2-aryl-*N*-tosylaziridines cyclized with phenyl isothiocyanate using  $\text{BF}_3 \cdot \text{OEt}_2$  and



**Scheme 4** Possible mechanism for the synthesis of thiazolidine derivatives **7** using Lewis acid-catalyzed domino ring-opening cyclization

TBAHS in  $\text{CH}_2\text{Cl}_2$  at  $0\text{ }^\circ\text{C}$ , regioisomers of 2-iminothiazolidines were produced in high yields (up to 99%). With the same previous reaction conditions, except the amount of catalyst, *trans*-2, 3-disubstituted aziridines gave single diastereomers (de, ee > 99%) related 2-iminothiazolidines in 90% yield (Scheme 4).

Multicomponent reactions are used for synthesis of various thiazolidine derivatives under different environmental conditions, some of which are summarized in Table 1. The comparison in Fig. 3 is illustrated in two points, concerning the addition of more than two components in a single step without considering their sequence [61]. In past years, researchers reviewed the mechanistic and chemical properties of MCRs, their sustainability and relation with biological activity [60, 61].

The anti-glioma activity and cytotoxicity of the thiazolidin-4-ones were evaluated by Da Silva and coworkers [62]. In this procedure, primary amines, aldehyde and mercaptoacetic acid were reacted via one-pot MCR in the presence of  $\text{BF}_3$  and *p*-toluenesulfonic acid (PTSA) and formed derivatives of thiazolidin-4-one (Scheme 5). Pyridine containing thiazolidinones gave good antitumor activity through decrease in cell feasibility of glioblastoma multiform cells. Among all synthesized derivatives, **9b**, **9e**, **9g** and **10e** exhibited potent antitumor effect against reference cells.


Recently, Rahim et al. [63] reported a novel and efficient method for the synthesis of arylhydrazide bearing thiazolidinone and analyzed them for  $\alpha$ -amylase and urease inhibitors. In this protocol, hydrazine hydrate and 4-cyanobenzoate were refluxed with substituted aldehydes/acetophenone, resulting in corresponding Schiff

**Table 1** Different multicomponent reactions for the synthesis of thiazolidine derivatives


S. No.	Reactant	Conditions	Product	Ref.	
1	R-NH <sub>2</sub>	CS <sub>2</sub>		H <sub>2</sub> O, rt, 1h	[155]
2	R-NH <sub>2</sub>	CS <sub>2</sub>		THF, rt, 10-30 min. then EtOH, DIPEA	[156]
3	R-NH <sub>2</sub>	RNCS		CHCl <sub>3</sub> , rt	[157]
4	R-NH <sub>2</sub>	RNCS		DMF, rt	[158]
5	R-NH <sub>2</sub>	CS <sub>2</sub>		K <sub>2</sub> CO <sub>3</sub> (aqu.), rt, 1h	[159]
6		ClCH <sub>2</sub> COOH	RCHO	MW, H <sub>2</sub> O	[160]
7				CuI, DIPEA, CH <sub>2</sub> Cl <sub>2</sub> , 0°C to rt, 16h	[161]
8				ultrasound, water additives	[162]

base **11**, which further reacted with thioglycolic acid using acetic acid to give the final product thiazolidinone **12** (Scheme 6). A screening of **11a-r** and **12a-o** was conducted for  $\alpha$ -amylase and urease inhibitory processes, respectively. Among all compounds, six derivatives, **11b**, **11e**, **11f**, **11j**, **11k**, **11r**, and nine derivatives, **12a**, **12b**, **12e**, **12f**, **12g**, **12h**, **12j**, **12k** and **12l**, were highly potent inhibitors as compared to reference drug acrobase ( $\alpha$ -amylase inhibitor) and thiourea (urease inhibitory), respectively.





**Scheme 5** Synthesis of thiazolidinone derivatives **9** and **10** in the presence of PTSA/BF<sub>3</sub>




**Scheme 6** Synthesis of substituted thiazolidinone derivatives


## 2.2 Base-Catalyzed Synthesis

Kaboudin and colleagues [64] investigated a novel, facile, one-pot and high-yielding protocol for thiazolidin-4-one derivatives from one-pot, four-component condensation and cyclization of various benzaldehydes **13** and hydrazine with  $\alpha$ -halo ketones and allyl isothiocyanate (Scheme 7). In order to determine the optimal reaction conditions, the reaction was carried out using different catalysts like NaOH, pyridine, DBU and Et<sub>3</sub>N at different temperatures, and the best results were achieved in the presence of the Et<sub>3</sub>N catalyst with 7 h of reflux in methanol. The plausible reaction mechanism was decoded as the hydrazine reacting with allyl isothiocyanate and aldehyde to afford an intermediate, which showed nucleophilic substitution with  $\alpha$ -chloroacetyl chloride and underwent intramolecular cyclization, generating novel thiazolidin-4-one **14** (Scheme 8). Easy accessibility of reactant, operation simplicity, mild reaction conditions, clean reaction profile, high yields and purity of products were the notable advantages of this protocol.

An efficient and greener one-pot method for the synthesis of a range of bioactive tetrahydrothiazolo[3,2-*a*]quinolin-6-ones was employed using cysteamine hydrochloride, 1,1-bis(methylthio)-2-nitro ethylene, trimethylamine with aromatic aldehyde and dimedone in H<sub>2</sub>O/EtOH and triethylamine by Bayat and coworkers [65] (Scheme 9). According to the investigation of the reaction mechanism, cysteamine hydrochloride (**15**) initially reacted with 1,1-bis(methylthio)-2-nitroethene (**16**) in H<sub>2</sub>O/EtOH to furnish 2-(nitromethylene)thiazolidine (**18**). Subsequently, aromatic aldehyde (**19**) on condensation with dimedone (**17**) formed an adduct. Further




**Scheme 7** Synthesis of thiazolidine derivatives **14(a-r)** using basic catalyst



**Scheme 8** Putative mechanism for the synthesis of compound **14**. Modified from Ref. [64]


Michael addition of 2-(nitromethylene)thiazolidine **16** and the adduct resulted in the formation of an intermediate, followed by imine–enamine tautomerization, then nucleophilic addition of an amino moiety to the carbonyl group, and, finally, intramolecular cyclization produced desired products **20(a–p)** in 75–94% yields (Scheme 10). The remarkable features of this new protocol were operational simplicity, mild reaction conditions, easily available substrates, easy workup, high yield in short time periods and a highly environmentally benign method.

Santeusanio et al. [66] reported a domino reaction, also known as a cascade reaction, consisting of at least two subsequent reactions where segregation of the intermediate is not required and occurs intramolecularly with advantages like less waste generation, fast reaction and high atom economy. In the multifarious thiazolylidene ring congregation, ATAs ( $\beta$ -amidothioamides) can act as heteromononucleophiles or heterodinucleophiles. A library of thiazolylidene derivatives **24** and **25** was synthesized by the reaction of ATAs **21** and DDs **22** and **23** (Scheme 11). As a result, two types of products were formed with different



Ar(yield%) = 4-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>(89), 3-ClC<sub>6</sub>H<sub>4</sub>(90), 4-ClC<sub>6</sub>H<sub>4</sub>(92), 4-BrC<sub>6</sub>H<sub>4</sub>(94), C<sub>6</sub>H<sub>5</sub>(88), 2-ClC<sub>6</sub>H<sub>4</sub>(82), 4-FC<sub>6</sub>H<sub>4</sub>(78), 3-FC<sub>6</sub>H<sub>4</sub>(75), 3,4-(OCH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(88), 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>(85), 4-(Me)<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>(88), 4-OHC<sub>6</sub>H<sub>4</sub>(79), 2-OH-5-BrC<sub>6</sub>H<sub>4</sub>(86), 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(87), 2-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(78), 4-COOCH<sub>3</sub>(89).


**Scheme 9** Synthesis of thiazolidine derivatives **20a–p** using Et<sub>3</sub>N



**Scheme 10** Possible mechanism for the synthesis of thiazolidine derivatives **20**. Modified from Ref. [65]

pathways. A variety of solvents such as MeOH, THF and DMF were used for the completion of reaction without using a base, but these conditions did not give satisfactory results. Further study showed that when the reaction was performed with an organic base in  $\text{CHCl}_3$  at ambient temperature, the best results were obtained.

A simple, more efficient, cost-effective and convenient synthetic procedure for the synthesis of 2-heteroaryliino-1,3-thiazolidin-4-ones using 3-aminothiophenes, chloroacetyl chloride and ammonium thiocyanate along with different solvents and catalysts was reported by Revelant et al. [67] (Scheme 12). Compounds **26** and **27** were found effective in antiproliferative activity against five cancer cell lines, i.e. MDA-MB-231, HCT116, HT29, MCF7 and SW620.




**Scheme 11** Synthesis of thiazolidine derivatives **24** and **25** using different ring closure pathways. Modified from Ref. [66]

Yahiaoui and coauthors [68] described a reliable and simple protocol for the preparation of 2-thioxo-thiazolidin-4-ones **28** by condensation of aromatic amines and  $\text{CS}_2$  using  $\text{NH}_4\text{OH}$  and chloroacetic acid, and the compounds were further treated with  $\text{CH}_3\text{CN}$  under basic conditions (Scheme 13). The authors also developed a combined experimental and theoretical approach on the molecular structure of 2-thioxo-3*N*-(2-methoxyphenyl)-5 [4'-methyl-3'*N*-(2'-methoxyphenyl)thiazol-2'(3'*H*)-ylidene] thiazolidin-4-one.


Hassan and colleagues [69] synthesized new thiazolidine derivatives **30(a–d)** from hydrazide **29**, ethyl bromoacetate and anhydrous sodium acetate using ethanol, and also evaluated their anticancer activity against HepG2, PC-3, MCF-7 and A549 human cancer cell lines (Scheme 14). However, these compounds did not show good anticancer activity.

### 2.3 Nanoparticle-Catalyzed Synthesis


Nanoparticles have a large surface-to-volume ratio and active coordination parts, compared to bulk materials. Nano-heterogeneous catalyst shows high activity, low energy consumption and 100% selectivity; therefore, these are suitable for the preparation of bioactive heterocyclic compounds [70, 71]. Recently, magnetic nanoparticles have received great attention because of their enormous benefits such as cost-efficiency, good stability, easy separation and high surface area [72]. Coating of nanoparticles with various materials like copper [73], chitosan [74] and L-proline [75] improves their activity [76].



**Scheme 12** Synthesis of compounds **26** and **27** under basic conditions




**Scheme 13** Synthesis of 2-thioxo-3*N*-(2-methoxyphenyl)-5[4'-methyl-3'*N*-(2'-methoxyphenyl)thiazol-2'(3'*H*)-ylidene]thiazolidin-4-one



**Scheme 14** Synthesis of substituted thiazolidine derivatives under basic conditions

Safaei-Ghomi and his group [77] developed a novel, efficient, pseudo-five-component preparation of bis-thiazolidinones **31(a–j)** from substituted benzaldehyde, ethylenediamine and TGA (**3**) with nano- $\text{CdZr}_4(\text{PO}_4)_6$  as a retrievable and robust catalyst (Scheme 15). The 0.6 mol% catalyst loading was sufficient for the good yield of products. It was observed that the best results were obtained with aromatic aldehydes with electron-withdrawing groups (EWG) as compared to electron-donating groups (EDG). The catalyst  $\text{CdZr}_4(\text{PO}_4)_6$  provided the surface to carry out the reaction. Primarily imine formed as an intermediate by the reaction of benzaldehyde and ethylene diamine on the surface of the catalyst, which activated the C=O, C=N and S–H groups. Then, attack by the sulfur atom on the activated imine group occurred, followed by intramolecular cyclization to give thiazolidinones (Scheme 16).


Nano- $\text{CoFe}_2\text{O}_4@/\text{SiO}_2/\text{PrNH}_2$ , an appropriate addition in the field of synthetic chemistry, was achieved by Safaei-Ghomi and coworkers [78]. The treatment of  $\text{CoFe}_2\text{O}_4@/\text{SiO}_2$  with APTES in refluxing toluene led to the concept of  $\text{CoFe}_2\text{O}_4@/\text{SiO}_2/\text{PrNH}_2$  nanoparticles as a peculiar magnetically recyclable, green




R(yield%)= 4-chloro-benzaldehyde(88), 4-methylbenzaldehyde(81), benzaldehyde(84), 4-nitrobenzaldehyde(89), 3-nitrobenzaldehyde(86), pyridine-2-carbaldehyde(86), pyridine-3-carbaldehyde(85), pyridine-4-carbaldehyde(86), 2-chlorobenzaldehyde(86), 4-iso-propylbenzaldehyde(80).

**Scheme 15** Synthesis of bis-thiazolidinones using nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub>


and efficient catalyst, and the compound was found to be effective in the synthesis of 1,3-thiazolidin-4-ones **32** via MCRs of aniline, chloro benzaldehyde and TGA with different solvents (Scheme 17). The catalyst was reusable for seven progressive cycles. This novel reaction was carried out on different aromatic aldehydes and aniline, and it was concluded that the EWG in aldehydes reacted faster as compared to EDGs. Two mechanisms have been proposed for the reaction. In the first mechanism, aldehyde and amine interacted to form imine intermediate, then



**Scheme 16** Mechanism for the synthesis of bis-thiazolidinones using nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub>. Modified from Ref. [77]



**Scheme 17** Synthesis of 1,3-thiazolidin-4-ones using nano-CoFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>/PrNH<sub>2</sub>




**Scheme 18** Mechanism for the synthesis of 1,3-thiazolidin-4-ones using nano-CoFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>/PrNH<sub>2</sub>. Modified from Ref. [78]


a sulfur atom of mercaptoacetic acid attacked the carbon atom of imine which was catalyzed by CoFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>/PrNH<sub>2</sub> NPs followed by intramolecular cyclization to give thiazolidinones (Pathway A). In the second mechanism, initially, formation of amide took place from aldehyde, thioglycolic acid and amine followed by cyclocondensation of a carbonyl group of aldehyde with sulfur and a nitrogen motif catalyzed by the same NPs to give cyclic compounds, thiazolidinones (Pathway B) (Scheme 18).

The convenient and green FeNi<sub>3</sub>-ionic liquid (IL) magnetic nanoparticle (MNP)-promoted solvent-free, one-pot synthesis of varied 1,3-thiazolidin-4-ones from amine, aldehyde and TGA in excellent yields was established by Sadeghzadeh et al. [79] (Scheme 19). The use of robust, stable, easily recoverable, inexpensively synthesized and reusable magnetic ILs supported on FeNi<sub>3</sub> nano-catalyst made the reaction protocol eco-friendly and of high synthetic utility. This protocol has significant additional advantages such as being solvent-free, an immobilization technique and a fast reaction procedure. The authors applied various






**Scheme 19** Synthesis of 1,3-thiazolidin-4-one using FeNi<sub>3</sub>-IL MNPs



**Scheme 20** Mechanism for the synthesis of 1,3-thiazolidin-4-one using FeNi<sub>3</sub>-IL MNPs. Modified from Ref. [79]

conditions like different solvents and catalyst to obtain the sustainable reaction conditions, and it was observed that 0.001 g of FeNi<sub>3</sub>-IL MNPs at 50 °C without solvent was suitable for the reaction. The predicated mechanism for this synthesis was explained as the condensation of aldehyde and amine to form an imine intermediate which combined with thioglycolic acid to furnish the intermediate that consequently cyclized to afford product **33** (Scheme 20).

An adept, feasible, one-pot synthesis of 1,3-thiazolidin-4-one derivatives was introduced by Azgomi et al. [80] using MNPs@SiO<sub>2</sub>-IL (nano-Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>-supported ionic liquid). The reaction was derived from the condensation of arylaldehyde, thioglycolic acid and anilines in solvent-free conditions with high to excellent yields (Scheme 21). The pathway of reaction involved MNPs@SiO<sub>2</sub>-IL, which activated oxygen of the carbonyl group and amine for the formation of an imine intermediate via enhancing the electrophilicity of the carbonyl group. The thioglycolic acid attacked the activated imine intermediate and formed a new intermediate, which, upon activation by catalyst MNPs@SiO<sub>2</sub>-IL, produced **34(a-j)** (Scheme 22). The authors studied the effect of various catalysts such as dicarbethoxydihydrocollidine (DDC), Baker's yeast, SiO<sub>2</sub>, HClO<sub>4</sub>-SiO<sub>2</sub>,




**Scheme 21** Synthesis of 1,3-thiazolidin-4-one **34** using MNP@SiO<sub>2</sub>-IL

H<sub>2</sub>SO<sub>4</sub>-SiO<sub>2</sub>, TfOH-SiO<sub>2</sub> (trifluoromethanesulfonic acid-SiO<sub>2</sub>), Bi(SCH<sub>2</sub>COOH)<sub>3</sub> and MNPs@SiO<sub>2</sub>-IL in different solvents like EtOH, H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, EtOAc, DMF, CH<sub>3</sub>CN, THF and toluene and also under solvent-free conditions. The use of 0.0007 g of MNPs@SiO<sub>2</sub>-IL at 70 °C without solvent exhibited the best results. The catalyst was reused for ten runs without considerable loss in its activity.


## 2.4 Ionic Liquid-Assisted Synthesis

Ionic liquids are powerful solvents and catalysts, which have various advantages as they are nonvolatile, have low vapor pressure, minimize chemical waste, have a wide range of anion and cation combinations, have high chemical and thermal stability and are easily recyclable.


Subhedar et al. [81] observed one-pot, multicomponent reaction (MCR) using [Et<sub>3</sub>NH][HSO<sub>4</sub>] as a catalyst, and the products were found in excellent yields with



**Scheme 22** Mechanism for the synthesis of 1,3-thiazolidin-4-one **34** using MNP@SiO<sub>2</sub>-IL. Modified from Ref. [80]



**Scheme 23** Synthesis of 1,3-thiazolidin-4-ones using [Et<sub>3</sub>NH][HSO<sub>4</sub>]




**Scheme 24** Synthesis of thiazolidine derivatives using ionic liquids

a high purity, whereas lower yields were obtained in the absence of the catalyst. An environmentally and highly efficient protocol for 1,3-thiazolidin-4-ones was prepared from cyclocondensation of aniline, aromatic aldehyde and thioglycolic acid with [Et<sub>3</sub>NH][HSO<sub>4</sub>] (Scheme 23). The catalyst was reused five times, and high yields (80%) were obtained at 80 °C when 25 mol% of the catalyst was used. 1,3-Thiazolidin-4-ones were tested *in vitro* for their antimycobacterial activity, antimicrobial activity and cytotoxicity. This analysis showed that these derivatives displayed excellent selectivity towards dormant *M. Bovis BCG* and *MTB H37Ra* strains.


Chen et al. [82] reported a one-pot, three-component condensation reaction of substituted 2-aminobenzimidazoles, isothiocyanate and triethylamine using ethylene dichloride (EDC) as a solvent and formed 2-imino-1,3-thiazolidines and 2-imino-1,3-thiazolines (Scheme 24). In this protocol, 2-aminobenzimidazole adhered on ionic liquid (IL), then isothiocyanate proceeded with IL-anchored 2-aminobenzimidazole, yielding isothiurea which combined with 1,2-dichloroethene by inter- and intramolecular processes and generated 2-imino-1,3-thiazolidines. ILs provided high atom economy and simplicity in product isolation (Scheme 25).

Malla and colleagues [83] investigated an ingenious, greener, solvent-free, high-yielding, one-pot, three-component synthesis of thiazolidine derivatives from 1,3-diketones, cyanates and ethylchloroacetate using [Et<sub>3</sub>NH][HSO<sub>4</sub>] IL as a catalyst, which afforded good yields (92–98%) with high purity (Scheme 26).




**Scheme 25** Mechanism for the synthesis of thiazolidines **36** using ionic liquids. Modified from Ref. [82]

Here,  $[\text{Et}_3\text{NH}][\text{HSO}_4]$  is an inexpensive, eco-friendly catalyst, stable in water and air, exhibited both catalytic and medium engineering capability, is recyclable up to five runs without any significant loss of catalytic activity and also eliminated the additional use of the solvent. According to the possible reaction mechanism, initially, ionic liquid protonated the cyanates to furnish an intermediate, which underwent nucleophilic addition with 1,3-diketones and formed a new intermediate, which further reacted with ethylchloroacetate with consequent expulsion of HCl. The nitrogen of the compound attacked the carbonyl group and eliminated ethanol to form a C–N bond and finally formed the products **37** (Scheme 27). The authors applied diverse catalysts like  $[\text{Et}_3\text{NH}][\text{HSO}_4]$ ,  $[\text{Me}_3\text{NH}][\text{HSO}_4]$ ,  $[\text{Et}_2\text{NH}_2][\text{H}_2\text{PO}_4]$  and  $[\text{Me}_3\text{NH}][\text{CH}_3\text{COO}]$ , and various solvents such as dimethyl sulfoxide (DMSO), EtOH, DMF,  $\text{CH}_3\text{NO}_2$ , toluene and  $[\text{Et}_3\text{NH}][\text{HSO}_4]$  in different amounts at varied temperature for optimization of the reaction conditions w.r.t. good yields and time (Table 2). The solvent also played a crucial role in the yields of reaction; i.e. nonpolar solvent (85%) > polar-aprotic solvent (55–74%) > polar-protic solvent (52%). However, the best results were obtained at 120 °C



**Scheme 26** Synthesis of thiazolidine derivatives **37** using  $[\text{Et}_3\text{NH}][\text{HSO}_4]$




**Scheme 27** Possible mechanism for the synthesis of thiazolidinones **37**. Modified from Ref. [83]

in 20 mol% of IL as a reaction media under solvent-free conditions. High atom economy, operational simplicity, an environmentally friendly nature, easy catalyst synthesis, low waste material, mild conditions and shorter reaction time are the notable advantages of this procedure.

Novel thiazolidinone derivatives **38** were synthesized by Sadeghzadeh and coauthors, [84] in which aldehyde, amine and thioglycolic acid were reacted using heterogeneous catalyst  $\text{Fe}_3\text{O}_4/\text{SiO}_2/\text{Salen}/\text{Mn}/\text{IL}$  MNPs under solvent-free conditions at ambient temperature with good to excellent results (Scheme 28). Here, the catalyst offered several advantages viz. ease of synthesis, easy recovery by an external magnet, operational simplicity and reusability up to six runs without any significant loss of activity. The authors applied various catalysts such as  $\text{SiO}_2/\text{Salen}/\text{Fe}_3\text{O}_4/\text{Mn}/\text{IL}$  MNPs, phosphotungstic acid,  $\text{NbCl}_5$  [niobium(v) chloride], PEG- $\text{SO}_3\text{H}$  (sulfonated polyethylene glycol),  $\text{InCl}_3$  (indium chloride),  $\text{Pd}(\text{PPh}_3)_4$ , cerium(IV) ammonium nitrate and nano- $\text{SiO}_2/\text{TiO}_2/\text{RuO}_2/\text{Pd}/\text{FeNi}_3$  in different solvents ( $\text{H}_2\text{O}$ , EtOH, THF,  $\text{CH}_2\text{Cl}_2$ , *n*-hexane) at different temperatures for optimization of the reaction condition w.r.t. yields and time. By the study, they concluded that  $\text{Fe}_3\text{O}_4/\text{SiO}_2/\text{Salen}/\text{Mn}/\text{IL}$  MNP without solvent at room


**Table 2** Synthesis of thiazolidinone derivatives using different substituents (**37a–37n**)

Product	Substituents			Time (min.)	Yield (%)
	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>		
<b>37a</b>	-CH <sub>3</sub>	-CH <sub>3</sub>		25	98
<b>37b</b>	-CH <sub>3</sub>	-CH <sub>3</sub>	CH <sub>2</sub> =CH-CH <sub>2</sub> -	26	96
<b>37c</b>	H			30	94
<b>37d</b>	H		CH <sub>2</sub> =CH-CH <sub>2</sub> -	35	92
<b>37e</b>	H			35	93
<b>37f</b>	H		CH <sub>2</sub> =CH-CH <sub>2</sub> -	29	94
<b>37g</b>	H			34	92
<b>37h</b>	H		CH <sub>2</sub> =CH-CH <sub>2</sub> -	30	95
<b>37i</b>	H			28	96
<b>37j</b>	H		CH <sub>2</sub> =CH-CH <sub>2</sub> -	32	97
<b>37k</b>	H			35	93
<b>37l</b>	H		CH <sub>2</sub> =CH-CH <sub>2</sub> -	26	97
<b>37m</b>	H			27	98
<b>37n</b>	H		CH <sub>2</sub> =CH-CH <sub>2</sub> -	34	95




- a; R = Me, R' = Me(94%), b; R = H, R' = Me(91%), c; R = NO<sub>2</sub>, R' = Me(90%)  
 d; R = H, R' = H(93%), e; R = Cl, R' = H(94%), f; R = Me, R' = H(88%)  
 g; R = NO<sub>2</sub>, R' = H(92%), h; R = H, R' = Cl(90%), i; R = H, R' = NO<sub>2</sub>(92%)

**Scheme 28** Synthesis of 1,3-thiazolidin-4-one **38** using Fe<sub>3</sub>O<sub>4</sub>/Salen/Mn/IL MNPs



**Scheme 29** Synthesis of 1,3-thiazolidin-4-ones using DES




**Scheme 30** Synthesis of 2-imini-thiazolidine via [3+2] cycloaddition reaction

temperature gave the best results. This method has many merits, including high atom economy, synthetic efficiency, solvent-free conditions and shorter reaction time.

## 2.5 Eutectic Solvent-Assisted Synthesis

Yedage and his group [85] synthesized 1,3-thiazolidin-4-ones by MCRs with aniline, benzaldehyde and TGA (**3**) in the presence of choline chloride:glycerol (1:2) as DESs (Scheme 29). DESs are the particular type of ionic solvents formed by combination of a Lewis acid, Brønsted acid and a base. These are used as an eco-friendly and reusable solvents or catalysts due to many characteristics like lower melting point as compared to individual components because of delocalization of charge on the whole mixture, high viscosity and inadequate density, so they can be liquid at the broad range of atmospheric conditions and incombustible. The mechanism of the reaction showed that DES firstly interacted with the oxygen of the carbonyl compound, and, simultaneously, the nitrogen atom of aniline attacked the carbon atom; then, imine was formed as an intermediate, which further reacted with TGA to form the product. At last, DES was removed and reused at least five times continuously without any damage.



**Scheme 31** Possible mechanism for the synthesis of 2-imino thiazolidine **40** via [3+2] cycloaddition. Modified from Ref. [86]


## 2.6 Catalyst- and Solvent-Free Synthesis

Dahiya et al. [86] investigated a series of 2-iminothiazolidines via DROC reaction without use of any catalyst and solvent (Scheme 30). An ecologically benign process containing inactive aziridine and aroyl isothiocyanates under the solvent-free conditions at room temperature produced 2-iminothiazolidines. Here, aroyl isothiocyanates played a role either as an ambient nucleophile ( $-\text{SCN}$  or  $-\text{NCS}$ ) or electrophile. When this reaction was accomplished with solvent, the yield was comparatively low. This process was examined with substituted aziridine and aroyl isothiocyanates, and the authors demonstrated that the synthesis was facile when aziridine bearing electron-donating groups and aroyl isothiocyanates having electron-withdrawing substituents were taken. The mechanism of the reaction showed that this methodology involved [3+2] cycloaddition reaction which occurred by the  $\text{S}_{\text{N}}2$  pathway. This was confirmed by the reaction of optically active aziridine and aryl isothiocyanate, and it gave optically active product. The lone pair on the nitrogen of aziridine made it a nucleophile, and its attack on the  $\text{sp}$  hybrid carbon of heterocumulene NCS formed a thiourea intermediate, whose sulfur atom attacked the benzylic site of aziridine, and ring opening occurred (Scheme 31).

## 2.7 Microwave-Assisted Synthesis


Microwave treatment promotes better thermal management of reactions which are temperature-sensitive, and produces uniform heating and increase product yields using mild conditions. Mahmoodi et al. [87] reported an appropriate, one-pot, three-component reaction for the preparation of thiazolidinones using  $\text{KSF@Ni}$  as a heterogeneous catalyst by the reaction of aldehydes, thiosemicarbazide and maleic anhydride under MWI (Scheme 32). Microwave MCRs have several advantages such as shorter reaction time, high product yields, cleaner reaction profile, minimal by-products, and greater efficiency and cost-effectiveness. Heterogeneous catalyst has special features such as a long life span, easy removal and recovery, an innocuous





R = 2,4-diCl(74%), 2,6-diCl(80%), 4-Cl(74%), 3-NO<sub>2</sub>(95%), 2-NO<sub>2</sub>(69%), 4-NO<sub>2</sub>(97%), 2-OH(90%), 4-OH(86%), H-(60%), 4-OCH<sub>3</sub>(70%)


**Scheme 32** Synthesis of thiazolidinone **41** using MW irradiation



**Scheme 33** Synthesis of new thiazolidine derivatives under MWI


nature, and is safe for storage. When the reaction was performed in the polar solvent, e.g. EtOH, DMF and MeOH, the reaction proceeded slowly. This method worked successfully under MWI at 70 °C and 50 psi in the mixture of DMF:toluene (1:1) in short reaction time (5 min) to give high yield (60%). The catalyst was recyclable for seven runs and gave almost the same yield of products. These products showed *in vitro* antibacterial activity against Gram-positive and Gram-negative bacterial strains *E. coli*, *P. aeruginosa*, *S. aureus* and *M. luteus*.

Sangeetha and coworkers [88] disclosed microwave-assisted, solvent-free synthesis of thiazolidine derivatives (**42**) using Amberlite IR-120H resin as a greener and reusable catalyst. 3/5-Alkyl-2,6-diarylpiperidin-4-ones were condensed with thiosemicarbazide and ethyl-2-bromopropionate under 250 W MWI, which afforded high yield of 2,6-diarylpiperidin-4-ylidene thiazolidin-4-one derivatives within 3–6 min. In contrast, in the conventional method, it took more time and gave comparatively low yields (Scheme 33). All the synthesized compounds were evaluated for *in vitro* antibacterial activity against five different bacterial strains *S. aureus*, *S. pyogenes*, *P. aeruginosa*, *K. pneumoniae* and *E. coli* and antitubercular activity against *M. tuberculosis* H37Rv, using streptomycin and isoniazid (INH) as standard drugs, respectively. Among all compounds, most displayed good antibacterial potency, and **42c** and **42d** showed high antitubercular activity.



R(yield%) = 2-Cl-C<sub>6</sub>H<sub>4</sub>(84), 2-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>(86), pyridine-2-yl(81), 3-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>(83), pyridin-3-yl(79), 4-Cl-C<sub>6</sub>H<sub>4</sub>(88), 4-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>(88), thiophene-2-yl(80), 4-isopropyl-C<sub>6</sub>H<sub>4</sub>(80), C<sub>6</sub>H<sub>5</sub>(82).


**Scheme 34** Synthesis of 1,3-thiazolidin-4-ones by nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub>



**Scheme 35** Mechanism for the synthesis of thiazolidine derivatives using nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub>. Modified from Ref. [90]

## 2.8 Ultrasound-Assisted Synthesis

Ultrasound irradiation is used as an alternative source of energy, providing a green pathway for various reaction pathways [89] and is based on the acoustic cavitation phenomenon. Safaei-Ghomi and coauthors [90] designed a facile, effective, one-pot, three-component synthesis of thiazolidinones from aldehyde, aniline and TGA using nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub> as an effective heterogeneous catalyst applying 60 W ultrasonic irradiation (Scheme 34). In this method, initially carbonyl groups of aldehyde and amine reacted to form an imine intermediate, which was further attacked by the sulfur atom of thioglycolic acid and underwent intramolecular cyclization by removal of water to furnish 1,3-thiazolidin-4-ones with 88% yield in 25 min. According to the reaction mechanism, it was suggested that




**Scheme 36** Synthesis of pseudopeptides containing rhodanine scaffolds

nano- $\text{CdZr}_4(\text{PO}_4)_6$  activated the carbonyl moiety of aldehyde and acid via coordinating with the carbonyl oxygen (Scheme 35). For comparative study, the authors employed diverse solvents, e.g.  $\text{H}_2\text{O}$ , EtOH, PhMe, THF and DMF, and catalysts like  $\text{H}_2\text{SO}_4$  and nano- $\text{SnO}/\text{ZrO}_2/\text{CdZr}_4(\text{PO}_4)_6$ . However, PhMe and nano- $\text{CdZr}_4(\text{PO}_4)_6$  were proved best as they gave high yields in short reaction time. The authors also studied the reaction under reflux conditions, but it displayed low yields in long reaction time as compared to ultrasonic irradiations. The use of nano- $\text{CdZr}_4(\text{PO}_4)_6$  as an efficient, highly active, easily recovered, eco-friendly catalyst with notable reusability without loss of its activity is the superior feature of this method. Simple reaction procedure, easily available reactants, use of sonochemical technique, high yields, synthetic efficiency, easy workup and short reaction time are the additional benefits of this protocol.


Shaabani et al. [91] reported novel MCRs for synthesis of pseudopeptide-linked rhodanine scaffolds using combination of tandem Michael/domino cycloaddition/Ugi reaction strategy. In this diversity-oriented synthesis, initially, primary amines, carbon disulfide and maleic anhydride were condensed to form thiazolidine **44**, which further reacted with benzaldehydes, aniline and isocyanides using water under ultrasound irradiations to produce final product **45** in good yields (Scheme 36). While using conventional stirring, the conversion rate was very slow. The use of easily available substrate, green solvent, ultrasound radiations and without use of any catalyst make the reaction protocol inexpensive and eco-friendly. The authors have also investigated the effect of solvents like DMF, THF, EtOH and  $\text{CH}_3\text{CN}$  on the reaction.

## 2.9 Catalyst-Free Synthesis

Salehitabar et al. [92] demonstrated the feasible methodology for the synthesis of ethyl 5-(alkylimino)-4-hydroxy-2-(arylimino)-3-alkylthiazolidine-4-carboxylates



**Scheme 37** Putative mechanism for the synthesis of compound **46**. Modified from Ref. [92]




- a**; R = H, R' =  $-CH_2Ar$  (81%),      **b**; R = 3-NO<sub>2</sub>, R' = C<sub>3</sub>H<sub>7</sub> (72%),  
**c**; R = 3-NO<sub>2</sub>, R' = C<sub>4</sub>H<sub>9</sub> (76%),      **d**; R = 3-OMe, R' = C<sub>3</sub>H<sub>7</sub> (67%).

**Scheme 38** Synthesis of thiazolidine-2-thiones without using catalyst


**46** from ethyl 3-chloro-3-(alkylimino)-2-oxopropanoate with 1-alkyl-3-arylthioureasin MeCN (acetonitrile) at room temperature via one-pot synthesis to afford various derivatives in good yields. The authors applied various solvents such as acetone, dry MeCN, tetrahydrofuran or toluene to achieve the best reaction conditions and concluded that dry MeCN was suitable and gave 73% yield at room temperature. Ease of operation, broad range of substrate, high synthetic utility, and good yields are the main advantages of this procedure (Scheme 37).

Halimehjani et al. [93] proposed the rapid, one-pot, three-component synthesis of thiazolidine-2-thiones using nitroepoxide, primary amine and carbon disulfide in H<sub>2</sub>O at ambient temperature with good yield of products (Scheme 38). Simplicity, efficiency, mild conditions, high yield of products and short reaction times are the attracting features of this protocol.


A novel catalyst-free, one-step synthesis of versatile thiazolidine derivative **48** has been developed by Aly and coworkers [94] using bithiosemicarbazones and DMAD in methanol to afford good yields (Scheme 39). All synthesized compounds



**Scheme 39** Synthesis of thiazolidine derivatives under catalyst-free conditions



**Scheme 40** APS-catalyzed synthesis of thiazolidinon-4-ones **49**




**Scheme 41** Synthesis of [60]fullerethiazolidinethiones **50** by DMF


were screened for antagonist of the leukotriene B<sub>4</sub> (LTB<sub>4</sub>) receptor. Some molecules were found potentially active towards BLT1 and BLT2 receptors.

## 2.10 Solvent-Free Synthesis

Ebrahimi and coworkers [95] reported the synthesis of 1,3-thiazolidin-4-one using APS (ammonium persulfate) as a catalyst under solvent-free conditions. The use of an economical catalyst, high yield and high atom economy are the benefits of this reaction. The synthesis involved cyclocondensation reaction of substituted aniline, benzaldehyde and thioglycolic acid (Scheme 40). The reaction was tested under different conditions viz. solvents, temperature and catalysts. The suitable conditions were solvent-free synthesis at 90 °C in the presence of 10 mol% of APS which yielded 84% product. To explore the synthetic utility of the protocol, different aldehydes were taken, and the yield of products was not sensitive to electronic variations and steric factor.



**Scheme 42** Mechanism for the synthesis of [60]fullerethiazolidinethiones **50**. Modified from Ref. [96]




$R_1 = t\text{Bu, Ph}$      $R_2 = n\text{-Pr, Ph, n-pent, i-pent, allyl, Bn,}$   
 $R_3 = \text{Ph, 2-Me-Ph, 3-Me-Ph, 4-Me-Ph, 4-OMe-Ph, 2-Me, 4-OMe-Ph,}$   
 $5\text{-OMe-Np, 4-Cl-Ph, 4-Br-Ph, cyclohexyl}$   
 $R_4 = \text{Ph, 3-Me-Ph, 2-OMe-Ph, 2-Naph, 4-Cl-Ph, 4-CN-Ph, Bn, n-Pr}$

**Scheme 43** Synthesis of thiazolidin-2-imines **51** using metal catalyst

## 2.11 Metal-Catalyzed Synthesis

A novel approach for the construction of [60]-fullerethiazolidinethiones from  $C_{60}$ , aliphatic amines and  $CS_2$  via Cu-catalyzed aerobic oxidative reaction was developed by Wu et al. [96] (Scheme 41). The authors applied various catalysts viz.  $CuSO_4 \cdot 5H_2O$ ,  $CuCl_2$ ,  $CuBr_2$ ,  $CuCl$ ,  $CuBr$ ,  $CuI$  and  $CuCl_2 \cdot 2H_2O$  in different solvents like DMF/o-DCB, o-DCB and DMF for good yields and reaction time. From the study, they concluded that the best results were obtained in the presence of  $Cu(OAc)_2 \cdot H_2O$  (20 mol%) with DMF/o-DCB (4:1). The suggested reaction mechanism showed that primary amine and carbon disulfide reacted in DMF and o-DCB in aerobic conditions to produce dithiocarbamic acid and further reacted with  $C_{60}$  to form aminium radical cation and  $C_{60}$  radical anion via a SET mechanism. Oxidative



**Scheme 44** Synthesis of 1,8-dioxo-octahydroxanthene derivatives containing 4-thiazolidinone **52(a–f)**


amination reaction took place in the  $C_{60}$  radical anion,  $O_2$  and aminium radical cation to form a  $C_{60}-N$  bond, followed by Cu-catalyzed aerobic oxidation to produce the  $C_{60}-S$  bond (Scheme 42).

Shehzadi et al. [97] developed an ingenious, high-yielding, one-pot four-component strategy for the synthesis of a library of thiazolidine-2-imines from aldehydes, alkynes, amines and isothiocyanates using Cu(I) and Zn(II) as composed catalyst, and examined their inhibitory activity against acetylcholinesterase (AChE) (Scheme 43). The authors applied different catalysts, solvents and temperature range using various ratios of reactants to optimize reaction parameters. According to the possible reaction mechanism, initially, metal acetylide attacked imine and generated an alkyn-amide nucleophile, which further reacted with isothiocyanate as an electrophile to form an intermediate. This intermediate has two nucleophilic atoms, thus two possibilities occur: nitrogen attack gave S-cyclized product thiazolidine-2-imine; and sulfur attack produced N-cyclized product imidazolidine-2-thione **51**. Single-crystal X-ray analysis confirmed the existence of 2-imino thiazolidine. All analogs demonstrated good inhibition activity, but derivative **51 s** exhibited 88-fold stronger inhibition ( $IC_{50}$ ,  $0.0023 \pm 0.0002 \mu\text{M}$ ) than neostigmine methyl sulfate (standard drug).

## 2.12 Multistep Synthesis

A series of novel 4-thiazolidinone containing 1,8-dioxo-octahydroxanthene derivatives were prepared by Robati and colleagues [98] by the reaction of 1,3-dicarbonyl cyclic compounds, nitro benzaldehyde and isothiocyanate with dialkylacetylene dicarboxylates in ethanol at ambient temperature via four-component reaction. The reaction was accompanied by an economical catalyst and less harmful solvent under mild reaction conditions, with larger product yields and fewer waste products. This procedure consisted of sequential addition of 1,3-cyclohexanedione and nitro benzaldehydes to form nitro 1,8-dioxo-octahydroxanthene derivatives, which underwent





**Scheme 45** Synthesis of bis spiro[5-methylindoline-3,2-(4H)thiazolidine]-2,40(1H)-dione derivatives **53**


reduction by  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  to produce the amino octahydroxanthene, that, upon refluxing with isothiocyanates, formed thioureas, which were then subjected to further reaction with dialkylacetylene dicarboxylate (DAAD) to form the final products **52** (Scheme 44).

A nitrogen equivalent of an aldehyde or ketone where the carbonyl group is exchanged by an imine or azomethine group is termed as a Schiff base. This is the most consequential moiety in the medicinal and pharmaceutical fields. Kandile et al. [99] developed a novel synthesis by reacting a Schiff base and TGA with anhydrous  $\text{ZnCl}_2$  or DMF, and the product, bis spiro[5-methylindoline-3,2-(4 H) thiazolidine]-2,40(1H)-dione[1,10]-biphenyl, was obtained (Scheme 45) and further scrutinized for antimicrobial activity.


The novel synthesis of 4-thiazolidinones was reported by Cihan-Üstündag et al. [100]. The protocol followed multistep synthesis as initially p-fluoro aniline reacted with  $\text{NaNO}_2$  and converted into the respective diazonium salt, which combined with ethyl-2-benzyl-3-oxobutanoate, which was further refluxed in concentrated HCl to produce ethyl 5-fluoro-3-phenyl-1H-indole-2-carboxylate. Ethyl 5-fluoro-3-phenyl-1H-indole-2-carboxylate was converted to respective hydrazide in the presence of hydrazine and was attacked by isothiocyanates to form substituted thiosemicarbazides, further cyclized using ethyl bromoacetate and fused sodium acetate to give desired products, 5-fluoro-N'-(4-oxo-3-substituted-1,3-thiazolidinon-2-ylidene)-3-phenyl-1H-indol-2-carbohydrazides **54(a-g)** (Scheme 46).

### 2.13 On-Surface Synthesis


The convenient, rapid, highly reproducible, one-pot, three-component synthesis of 4-thiazolidinone derivatives by the condensation of aldehyde, amine and TGA (**3**) at room temperature with silica gel as promoter was established by Thakare




**Scheme 46** Synthesis of thiazolidine derivatives **54(a–g)** via multistep synthesis



**Scheme 47** On-surface synthesis of thiazolidinone derivatives **55(a–w)**




**Scheme 48** Silica gel-mediated synthesis of thiazolidinone **55**. Modified from Ref. [101]



**Scheme 49** Synthesis of (Z)-2-imino-5-(Z)ylidene-N-substituted thiazolidines **56**

and coworkers [101] (Schemes 47, 48). The possible reaction pathway of the reaction indicated that aldehyde along with amine produced an imine intermediate which combined with thioglycolic acid to form another intermediate. Silica gel activated the carbonyl group by increasing their electrophilicity, and, consequently, intramolecular addition took place, and a new intermediate was obtained. On further removal of H<sub>2</sub>O molecule, the cyclized product of substituted 4-thiazolidinone was obtained. The authors investigated this reaction in various solvents like THF, Et<sub>2</sub>O, acetonitrile, dichloromethane and 1,2-dichloroethene, but dichloromethane was found to be the most suitable. The products were obtained without any workup procedure. Immediate synthesis and use of inexpensive and nontoxic chemicals make this protocol green and eco-friendly.



**Scheme 50** Synthesis of thiazolidine derivatives **57(a-b)**, **58** and **59(a-b)**


A simple and efficient silica gel-mediated synthesis of thiazolidine derivatives was developed by Singh and colleagues [102]. The derivatives were also examined as antiproliferative agents. In this method, propargyl amine and isothiocyanate reacted in CH<sub>2</sub>Cl<sub>2</sub> that underwent slow autoxidation at room temperature using CDCl<sub>3</sub> to afford thiazolidin-4-ones **56** in good to high yields (Scheme 49). The antiproliferative properties were investigated against HCT-116 (colon) and MCF7 (breast) cancer cell lines using MTT growth assay. Some of the synthesized analogs showed good activity without affecting normal cell lines.

### 3 Biological Activity of Thiazolidine Derivatives


#### 3.1 Antimicrobial Activity

Abdel Hafez and coworkers [103] developed a series of 2-(2-(1-(3,4-dimethoxyphenyl)ethylidene)hydrazono)-substituted thiazolidinone derivatives and tested them for antimicrobial activity against fungal strains (*A. niger* and *A. flavus*) and yeast strains (*S. cerevisiae*, *C. albicans*). Thiosemicarbazone derivatives (**57a** and **57b**) were refluxed with appropriate  $\alpha$ -halo carbonyl compounds such as chloroacetone and ethyl 2-bromopropionate using anhydrous sodium acetate in ethanol to produce corresponding thiazolidine analogs **58** and **59** (Scheme 50). Among all compounds, **57a**, **57b**, **58** and **59b** showed similar antifungal activity as compared to reference drug, ketoconazole. Compound **59b** was found the most potent for antifungal activity.

Obydenov et al. [104] synthesized 1,3-thiazolidin-4-one and pyrrolidine-2,3,5-trione motifs linked to (5Z)-[2-(2,4,5-trioxypyrrolidin-3-ylidene)-4-oxo-1,3-thiazolidin-5-ylidene]acetate derivatives via an exocyclic C=C bond, explained their isomeric form and also evaluated their in vitro fungicidal activity



**Scheme 51** Synthesis of 4-(4-oxo-1,3-thiazolidin-2-ylidene)pyrrolidine-2,3,5-trione derivatives **61(a–f)**



**Scheme 52** Synthesis of 1,3-thiazolidin-4-ones **62** and **63**

on *R. solani*, *A. solani*, *F. solani*, *C. coccodes* and *P. infestans* fungi, by the poisoned food technique. The reaction of thioamides and acetylene dicarboxylate in ethanol at ambient temperature gave 2-methylidene-1,3-thiazolidin-4-one derivatives, which reacted with oxalyl chloride in dry MeCN at 70 °C to produce 4-(4-oxo-1,3-thiazolidin-2-ylidene)pyrrolidine-2,3,5-trione derivatives **61(a–f)** in 57–87% yield. Here, compounds **60(a–f)** have a *Z* configuration of exocyclic bond in the C-5 position. In the C-2 position, configuration of the bond was affected by the solvent system, steric hindrance and intramolecular interaction such as hydrogen bonding. The authors also explained the pathway of isomerization of compounds **61(a–f)** as illustrated in Scheme 51. Compound **61b** was found to be most potent toward all the strains with EC<sub>50</sub> values of 0.052–0.445 mg/mL using Consento as the standard drug.


**Table 3** The activity of most potent chlorophenylthiosemicarbazones against Gram-positive bacteria determined on the basis of MIC (minimal inhibitory concentration, in mg/L and  $\mu\text{M}$ ) and MBC (minimal bactericidal concentration, in mg/L and  $\mu\text{M}$ ) with cytotoxic effect on human embryonic kidney cells (HEK-293) after 24 h of incubation

Compound	<i>S. aureus</i>		<i>S. aureus</i>		<i>B. subtilis</i>		EC70 $\pm$ SD (mg/L) (toxicity threshold)
	ATCC 6538		ATCC 25923		ATCC 6633		
	MIC	MBC	MIC	MBC	MIC	MBC	
<b>76a</b>	3.91	3.91	3.91	62.5	31.25	125	30.82 $\pm$ 3.73
	8.4	8.4	8.4	135	67.5	270	
<b>76b</b>	3.91	> 1000	3.91	> 1000	7.81	62.5	21.28 $\pm$ 3.84
	7.9	> 2010.6	7.9	> 2010.6	15.7	125.7	
<b>77a</b>	7.81	250	7.81	250	7.81	250	14.86 $\pm$ 1.12
	16.9	542.4	16.9	542.4	16.9	524.4	
<b>77b</b>	7.81	500	7.81	500	7.81	500	10.94 $\pm$ 1.35
	16.9	1084.8	16.9	1084.8	16.9	1084.8	
<b>79g</b>	31.25	> 1000	7.81	> 1000	3.91	62.5	19.01 $\pm$ 3.80
	63.7	> 2036.9	15.9	> 2036.9	8	127.3	
Cefuroxime	0.98	–	0.49	–	15.63	–	
	2.3		1.2		36.8		


Trotsko and coauthors [105] synthesized (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid derivatives using thiourea and maleic anhydride as starting materials under different reaction conditions, as illustrated in Scheme 52, and evaluated them for antibacterial activity using broth microdilution method. Cefuroxime and oxacillin were used as standard drugs. For reference strain, American Type Culture Collection (ATCC) *B. subtilis*, *M. luteus*, *B. cereus*, *S. aureus* and *S. epidermidis* for Gram-positive bacteria and *E. coli*, *K. pneumoniae*, *Proteus mirabilis* and *Pseudomonas aeruginosa* for Gram-negative bacteria were used. The researchers showed that the presence of an EWG at the phenyl ring was more potent as compared to an EDG; the geometry of the molecule did not affect the activity. Compound **64** was proved to be the most active compound with an MIC of 3.91 mg/L.

Trotsko and his group [106] synthesized thiazolidine-2,4-dione-based chlorophenyl thiosemicarbazone hybrids, which behaved as “hybrid pharmacophores” and were screened for antibacterial activity by broth microdilution technique using cefuroxime, ciprofloxacin and oxacillin as standard drugs. The authors combined two active moieties TZD (thiazolidine-2,4-dione) and thiosemicarbazides, which contain an N–N–C(=S)–N structural fragment, and they exhibited good potency of antibacterial activity at low nontoxic concentrations. The antibacterial activity was performed on 12 strains of Gram-positive and Gram-negative bacteria. Five derivatives (**65a**, **65b**, **66a**, **66b**, **68g**) were most potent against all used Gram-positive bacterial strains (Table 3). The pathway of the reaction is outlined in Scheme 53.

Xianga and colleagues [107] investigated a novel synthesis of thiazolidin-2-cyanamide derivatives, and their antimicrobial activity was determined against the T3SS of *Xanthomonas oryzae* on rice. The title compounds were developed




**Scheme 53** Synthesis of thiazolidine derivatives with highly active compounds




**a.** 4-chloro, **b.** 2-nitro, **c.** H, **d.** 3-fluoro, **e.** 3-nitro, **f.** 3-chloro, **g.** 4-bromo, **h.** 2,4-difluoro, **i.** 4-methoxy, **j.** 2-chloro, **k.** 4-fluoro, **l.** 4-tolyl, **m.** 2,6-difluoro, **n.** 2-fluoro

**Scheme 54** Synthesis of (thiazolidin-2-ylidene) cyanamide derivatives **69(a-n)**

in multistep synthesis, i.e. firstly Meerwein arylation took place in substituted aniline and formed an intermediate, 5-substituted phenyl-2-furancarboxylic acid,



**Scheme 55** Synthesis of thiazolidin-5-one derivatives **70(a-c)**




**Scheme 56** Synthesis of compounds **71** and **72**

which on reaction with thionyl chloride, 2-cyanoiminoradical-1,3-thiazolidine and  $K_2CO_3$  in acetonitrile solution furnished the desired compounds in good yields (Scheme 54). The authors concluded that the new compounds reduced the symptoms of disease, displayed antivirulence effects and did not affect bacterial growth.

Abdel-Galil et al. [108] synthesized thiazolidinone derivatives bearing a phenyl benzoate nucleus. The derivatives were screened for in vitro antibacterial activity against two types of bacterial strains, Gram-positive bacteria, *E. coli* and Gram-negative bacteria, *S. aureus*, and was compared with a standard chemotherapeutic drug (ampicillin) using disc diffusion method (Scheme 55). Knoevenagel condensation of thiazolidin-5-one derivatives with 4-formylphenyl benzoate in the presence of piperidine afforded arylidene products **70(a-c)**. Compounds **70(a-c)** showed good to moderate activity against reference strains.

Barakat et al. [109] described a scheme for the preparation of new derivatives of pyrrolidine/thioxothiazolidin-4-ones containing spiro-oxindole. The condensation reaction between isatin and L-proline generated azomethine ylide in situ, which underwent 1,3-dipolar cycloaddition with 5-arylidene-2-thioxothiazolidin-4-one (**71a** and **71b**) (prepared by a previously reported method by Knoevenagel condensation) to afford spiro-oxindole/pyrrolidine/thioxothiazolidin-4-one derivatives (**72a**, **72b**) in excellent yields (Scheme 56). These compounds were tested against two Gram-positive bacteria, *S. pneumonia* and *B. subtilis* and two Gram-negative bacteria, *P. aeruginosa* and *E. coli*, and they showed significant antibacterial properties.






**Scheme 57** Synthesis of compounds **73** and **74**

The antifungal activity of compounds was elucidated against *A. fumigates*, *S. racemosum*, *G. candidum* and *C. albicans* with the diffusion and serial dilution method. Fluconazole and amphotericin B were used as standard drugs. The structure of compounds **72a** and **72b** were determined with X-ray single-crystal diffraction, Hirshfeld surface analysis and DFT studies at the B3LYP/6-311G (d,p) level of theory. The 3D structures of both compounds were different, due to presence of diverse substituents at the phenyl ring and co-crystallization with solvent molecules. Compound **72a** docked with hydrophobic–hydrophobic interaction, but compound **72b** docked with both hydrophobic–hydrophobic and H-bonding interactions. Aminoglycoside phosphotransferase and lanosterol 14  $\alpha$ -demethylase were selected as target proteins for antibacterial and antifungal activity, respectively. Both compounds exhibited more antimicrobial activity against standard drugs. Compound **72b** gave better activity than **72a** against *B. subtilis*, *S. pneumonia* and *E. coli* and also showed high potency against antifungal treatment. The molecular docking study revealed that substitution on phenyl rings plays an important role in the geometry of compounds, which controls its behavior and mode of interaction. The study established that hybrid compounds **72a** and **72b** showed good results against skin infection and wound infection.

(Z)-5-Benzylidene-3-(5-heptadecyl-1,3,4-thiadiazol-2-yl) imino thiazolidin-4-one derivatives were prepared by Abdelmajeid et al. [110] and were further evaluated for their antimicrobial activity against *E. coli* (Gram-negative bacterial strain), *S. aureus* (Gram-positive bacterial strain) and *A. flavus* and *C. albicans* (two fungal species) by using modified Kirby–Bauer disc diffusion technique and Mueller–Hinton agar method. Equimolar quantities of stearic acid and thiosemicarbazide in the presence of POCl<sub>3</sub> produced 5-heptadecyl-1,3,4-thiadiazole-2-amine, which on chlorination with chloroacetylchloride formed 2-chloro-N-(5-heptadecyl-1,3,5-thiadiazole-2-yl)acetamide, which further reacted with KSCN to give 3-(5-heptadecyl-1,3,4-thiadiazol-2-yl)-2-imino thiazolidin-4-one (**73**), and **73** further combined with benzaldehyde to produce (Z)-5-benzylidene-3-(5-heptadecyl-1,3,4-thiadiazol-2-yl) imino thiazolidin-4-one (**74**) (Scheme 57). Compound **74** was more potent for antimicrobial activity as compared to compound (**73**). For positive control of antibacterial




**Scheme 58** Synthesis of 2-(2,4-dioxothiazolidin-5-yl/ylidene)acetic acid derivatives **75** and **76**


and antifungal activity, ampicillin and amphotericin B were used as standard drugs, respectively. Both products are safe for the environment and humans and are widely used in beauty products, fabric and dye industries as an emulsifier and wetting agent.

A class of novel analogs, thiazolidinediones (TZD), were prepared by Trotsko and coworkers [111], and the compounds were scrutinized for in vitro antiproliferative and antibacterial activity. The synthesis of target compounds by 2-(2,4-dioxothiazolidin-5-yl/ylidene)acetic chloride and salicylaldehyde through an efficient synthetic route is illustrated in Scheme 58. They were screened for antiproliferative activity by using normal human skin fibroblasts (BJ) and tumor cell lines, namely A549, HepG2 and MCF-7, were assessed by colorimetric MTT assay, and the antibacterial activity was determined in vitro against three Gram-positive and Gram-negative bacteria by broth microdilution. Compounds **75(a, e, f, g, i, j)** and **76(a, b)** showed antiproliferative activity against tumor cell lines. In the MCF-7 cells, the IC<sub>50</sub> value of compound **18** was 1.59 mg/mL, which was 13 times lower than irinotecan (reference drug) and the safety index (SI) value was threefold higher than the reference strain. Compounds **75f**, **75g** and **76b** showed high potency against Gram-positive bacteria, and compound **75g** seemed to be a promising agent for anti-cancer treatment.

Pânzariu and coworkers [112] demonstrated the synthesis of thiazolidine-4-one derivatives bearing a nitro-L-arginine methyl ester (NO<sub>2</sub>-Arg-OMe) and screened them for their antioxidant and antimicrobial activity. Novel arginine-linked thiazolidinone derivatives **77(a–j)** were synthesized in two steps; initially, one-pot condensation and cyclization reaction took place between ethyl 3-aminopropionate hydrochloride, aromatic aldehydes and TGA to form thiazolidine derivatives, which further reacted with *N*ω-nitro-L-arginine methyl ester hydrochloride in the presence of HOBt and EDC.HCl to furnish final products **77(a–j)** (Scheme 59). The in vitro




**Scheme 59** Synthesis of thiazolidine-4-one derivatives **77(a-j)**



**Scheme 60** Synthesis of biphenyl tetrazole-thiazolidineones **78(a-j)**

antioxidant activity was evaluated by ferric/phosphomolybdenum reducing antioxidant power assays and DPPH/ABTS scavenging assays. For investigation of antibacterial activity, two Gram-positive (*S. aureus*, *S. lutea*) and Gram-negative (*E. coli*, *P. aeruginosa*) bacterial strains were used, and for antifungal activity, *Candida* spp. (*C. glabrata*, *C. albicans*, *C. parapsilosis*) were used. Among all compounds, **77g** and **77h** displayed high free radical scavenging ability for DPPH and ABTS radicals, whereas **77j** and **77e** exhibited the highest activity for ABTS scavenging and ferric and phosphomolybdenum reducing antioxidant power, respectively. Significant antimicrobial activity was shown by **77j** which was found most potent against *P. aeruginosa*, *S. aureus* and *S. lutea* strains. These properties were stimulated in the presence of bromo and nitro groups at the phenyl ring of thiazolidinone.


Khan et al. [113] prepared a range of biphenyl tetrazole-thiazolidinedione derivatives and checked them as PDF enzyme inhibitors and for in vitro antibacterial activity. The preparation of biphenyl tetrazole-thiazolidinediones **78(a-j)** was carried out via condensation of biphenyl trityltetrazole-thiazolidinediones and THF using



**Scheme 61** Synthesis of benzothiazole incorporated thiazolidin-4-one **79**

sodium hydroxide (Scheme 60). The antibacterial activity was screened against bacterial strains *E. coli* and *B. subtilis* using a twofold serial dilution method, and dimethyl sulfoxide was used for solvent control. PDF enzyme was taken out from *E. coli* (NCIM-2931). All derivatives **78(a–j)** showed good to high activity against *E. coli* PDF-Ni enzyme and exhibited good binding properties. Among all synthesized compounds, **78b**, **78c** and **78h** were the most potent with IC<sub>50</sub> values of 16.25 mM, 18.00 mM and 17.25 mM, respectively. Compounds **78b**, **78c** and **78h** also showed antibacterial activity with an MIC range of 8.00–26.00 mg/mL, compared with standard ciprofloxacin. The SAR studies concluded that all reactants, thiazolidinedione (head group), acidic group (tetrazole) and the biaryl group played an important role in the inhibitory process, and the activity was also affected by substitution on the head group.

Gilani and coauthors [114] synthesized a series of unique thiazolidinones from *N*-(6-chlorobenzo[d]thiazol-2-yl)hydrazine carboxamide derivatives and evaluated them for in vitro antimicrobial activity against four bacterial strains, namely, *S. aureus* (Gram-positive bacteria) or *E. coli*, *P. aeruginosa*, *K. pneumoniae* (Gram-negative bacteria) and five fungal species, namely, *C. albicans*, *A. niger*, *A. flavus*, *M. purpureus* and *P. citrinum*, via the serial plate dilution method. The compounds displayed good antimicrobial activity at 12.5–200 µg/mL in DMSO. The products were obtained from the reaction of 2-amino-6-chloro-benzothiazole and sodium cyanate which further reacted with hydrazine hydrate solution in alcohol followed by ring closure between carboxamide and aromatic aldehydes. The authors reported that the most active compounds against all bacterial strains had methyl 2,4-dichloro and 4-nitro at the phenyl ring attached to the thiazolidinones ring, and on substituting the above groups with a chloro and acetyl group, their activity was decreased. When these groups were replaced by dichloro, methyl and phenoxy substituents,




**Scheme 62** Synthesis of N-substituted 5-(chromene-3-yl)methylene-2,4-thiazolidinediones **80a–g**



they showed high potency against all tested fungal strains. Here, the Gram-positive strain showed less activity as compared to Gram-negative strain (Scheme 61).

Nastasa et al. [115] designed a range of new 5-(chromene-3-yl)methylene-2,4-thiazolidinone derivatives and tested them for antimicrobial activity against two Gram-positive bacteria (*L. monocytogenes*, *S. aureus*), two Gram-negative bacteria (*E. coli*, *S. typhimurium*) and one fungus strain (*C. albicans*) with the agar diffusion method. Gentamicin and fluconazole were used as reference for antibacterial and antifungal activity, respectively. The Knoevenagel condensation reaction of 6,8-dichloro-4-oxo-4H-chromene-3-carbaldehyde, 2,4-thiazolidinedione and anhydrous sodium acetate in acetic acid, when treated with  $\alpha$ -bromoalkyl aryl ketones, dimethylformamide (DMF) and anhydrous potassium hydroxide produced N-substituted 5-(chromene-3-yl)methylene-2,4-thiazolidinediones (Scheme 62). All compounds showed low to high growth inhibitory effect against the tested strains, in which compound **80g** was found most potent at all used concentrations, while compound **80f** gave better effect, and compounds **80a** and **80e** exhibited similar activity as the standard drug gentamicin.

Novel N-substituted-1,3-thiazolidinone derivatives were synthesized by De Monte and coworkers [116], and their *in vitro* antifungal activity was determined against various phytopathogenic fungi, 22 *Candida* spp. (*C. tropicalis*, *C. albicans*, *C. krusei*, *C. glabrata*, *C. parapsilosis* and *C. sake*), and clotrimazole, ketoconazole, miconazole, fluconazole, tioconazole and amphotericin B were used as standard drugs. The thiazolidinones were designed via a contained N1 hydrogen moiety substituted with aromatic, heteroaromatic, cyclic and bicyclic structure, and on this basis it was classified into three series. Thiosemicarbazides were condensed with various carbonyl compounds using acetic acid and formed a thiosemicarbazone intermediate, which cyclized with ethyl bromoacetate in methanol and sodium acetate to form the thiazolidinone derivatives and further reacted with 4-nitrobenzyl



**Scheme 63** Synthesis of the N-substituted-1,3-thiazolidinone derivatives **81**




Method A : Microwave- assisted synthesis; glacial acetic acid; DMF; 110°C, 8-10 min

Method B : Conventional synthesis; glacial acetic acid; DMF; reflux; 2-3 hours

**Scheme 64** Synthesis of 3-(4-chloro-2-hydroxyphenyl)-2-substituted thiazolidin-4-ones **82(a-n)**


bromide and (chloromethyl)naphthalene and *N*-(chloromethyl)phthalimide via condensation to afford the desired products **81** (**A1–A26**, **B1–B26** and **C1–C26**) (Scheme 63). The SAR study showed that the presence of aliphatic and aromatic (both homo and hetero) moieties affected the inhibition activity of the compounds. The final compounds did not show satisfactory inhibition for bacterial activity, but compounds **81**(**A6**, **A7**, **A10**, **B6**, **C1** and **C6**) exhibited high antifungal activity against *Candida* spp. on Hep2 cells (human laryngeal epidermoid carcinoma). The molecular docking study explained the mechanism of the desired compounds and




**Scheme 65** Possible mechanism for the synthesis of 3-(4-chloro-2-hydroxyphenyl)-2-substituted thiazolidin-4-one **82**. Modified from Ref. [117]

revealed that these compounds mainly showed Van der Waals interactions with the hydrophobic binding pocket of active cells similar to the reference drug lanosterol.

Pansare and coworkers [117] introduced a one-pot three-component synthesis of 3-(4-chloro-2-hydroxyphenyl)-2-(substituted) thiazolidin-4-one using 2-amino-5-chlorophenol with different aldehydes in *N,N*-dimethylformamide (DMF) and glacial AcOH as a catalyst. The synthesis was carried out by both conventional and microwave heating. The compounds were further screened for antimicrobial activity (Scheme 64), and microwave-assisted synthesis afforded a high yield of the products. According to the mechanism, initially 2-amino-5-chlorophenol and benzaldehyde reacted to give imine intermediate. The imine reacted with mercaptoacetic acid and underwent intramolecular cyclization to form thiazolidinones (Scheme 65). All compounds were studied for *in vitro* antimicrobial activity against two Gram-positive bacteria (*B. subtilis* and *S. aureus*), two Gram-negative bacteria (*E. coli* and *S. typhimurium*) and four fungal strains (*C. albicans*, *A. flavus*, *A. niger* and *C. neoformans*) using a serial macrodilution method. Ciprofloxacin and ampicillin were used as reference antibacterial drugs, and fluconazole and miconazole were used as reference antifungal drugs. Among all the tested derivatives, **82f**, **82g**, **82i** and **82m** exhibited broad-spectrum activity, i.e. growth inhibitor against reference drug excluding fungus *A. niger*. Compounds **82g** and **82m** were more potent than the reference antifungal drug. All compounds also showed cytotoxicity on two cell lines, HeLa and MCF-7, using sulforhodamine B (SRB) assay. The SAR study revealed that structural variation and molecular strain affected the activity of the products. The activity of the compounds was controlled by substituents, i.e. an EDG on the phenyl ring enhanced the activity, whereas an EWG decreased activity. The remarkable features of this protocol were high yields with shorter reaction time, a unique, rapid and convenient synthesis, and all the compounds were non-cytotoxic.




**Scheme 66** Proposed mechanism for the synthesis of pyrone-linked 4-thiazolidinones compounds **83(a-d)**



**Scheme 67** Possible mechanism for the synthesis of 4-thiazolidinones **84(a-h)**






**R a** = 2-F (91%), **b** = 3-F (83%), **c** = 4-F (74%), **d** = 2-Cl (55%), **e** = 3-Cl (64%), **f** = 4-Cl (55%), **g** = 2-NO<sub>2</sub> (94%), **h** = 3-NO<sub>2</sub> (95%), **i** = 4-NO<sub>2</sub> (88%), **j** = 3-OH (86%), **k** = 4-OH (53%), **l** = 2-OMe (59%), **m** = 3-OMe (75%), **n** = 4-OMe (97%), **o** = 4-Me (86%), **p** = 2,6-diCl (91%)

**Scheme 68** Synthesis of 2-aryl-3-((piperidin-1-yl)ethyl)thiazolidinones **85(a-p)**

A series of new 4-thiazolidinones linked with a pyrone moiety were synthesized and screened for *in vitro* antimicrobial activity by Nechak et al. [118]. All compounds were screened against five microorganisms, *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* (ATCC 43300), *Staphylococcus aureus* (ATCC 25923) and *Candida albicans*. The 4-thiazolidinones **83(a-d)** were synthesized from thiosemicarbazones and ethyl 2-bromopropionate by refluxing in acetonitrile in high yields. Thiosemicarbazones and appropriate maleimide were refluxed with acetonitrile to produce thiazolidinones **83(a-h)**. The mechanism showed that in the synthesis of **83(a-d)**, thiosemicarbazones attacked bromoester, which underwent intramolecular cyclization (Scheme 66), while in the synthesis of **84(a-h)**, thiosemicarbazone attacked the double bond of maleimide, followed by ring opening and nucleophilic attack on the nitrogen atom (Scheme 67). Among all the compounds, **83(a-d)** and **84a-e** (except **84d**) showed high antibacterial activity against *Pseudomonas aeruginosa*. Compound **83d** exhibited antifungal activity against *Candida albicans*. Compounds **83c** and **84(a-h)** (except **84f**) exhibited significant antibacterial activity against *S. aureus* (ATCC43300), and compounds **83a-d** (except **83b**) displayed the highest activity against *S. aureus* (ATCC 25923). The SAR study revealed that substitution of the R group from -CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub> and H on compounds **83c** and **84e**, respectively, gave a broad spectrum of active drugs against *S. aureus* (Gram-positive bacteria) and *P. aeruginosa* (Gram-negative bacteria). In the inhibitory process, these compounds avert some intracellular and extracellular enzyme functions and microbial metabolism like DNA, RNA and protein synthesis of microorganisms.

Kunzler and colleagues [119] proposed a novel one-pot, two-step synthesis of 2-aryl-3-((piperidin-1-yl)ethyl)thiazolidinones **85(a-p)** from amine and arene aldehydes under refluxing toluene, and evaluated their antifungal and cytotoxic properties (Scheme 68). The *in vitro* antifungal activity was evaluated against *Candida albicans*, *Candida guilliermondii*, *Candida parapsilosis*, *Cryptococcus laurentii*, *Rhodotorula* sp., *Geotrichum* sp. and *Trichosporon asahii* using fluconazole as reference drug, and the cytotoxic properties were evaluated by Vero cells. The MIC and MFC values were found to be same for all synthesized compounds. The results showed that compounds **85h** and **85i** were 1.6 times more potent than fluconazole, whereas compounds **85b**, **85e**, **85g** and **85k** showed the same activity toward




**Scheme 69** Synthesis of 1,3-thiazolidin-4-one derivatives **86a–c**

*Rhodotorula* spp., and all compounds, especially **85g**, were found less toxic in cytotoxicity assay. These compounds worked best in growth inhibition against *Rhodotorula* sp. yeast. The SAR study explained that the change of electronic substituents did not directly affect growth inhibition against tested phytopathogens. Developments in recent decades in the medicinal field have generated serious problems in which pathogenic bacteria continuously develop resistance to the currently used antibacterial drugs. Discovery of agents which will block pathogenic mechanisms rather than killing the infecting microbe will help overcome bacterial resistance and will aid in the development of effective treatments.

### 3.2 Anticancer Activity

A series of novel thiazolidinones with a 3-hydroxy-2-naphthoic motif was synthesized and tested for in vitro cytotoxicity against both HepG2 and human renal cell adenocarcinoma (769-P). The in vivo impact of the compounds on the CNS of mice was studied by Popioleka and coauthors [120]. 1,3-Thiazolidin-4-one derivatives (**86a–c**) were prepared via reaction of 3-hydroxy-2-naphthoic acid hydrazide with aldehydes followed by cyclization with thioglycolic acid in dioxane (Scheme 69). For reference cell lines, rat cardiac myoblasts (H9c2) and GMK were used. Compound **86c** was most potent and selective against 769-P cell lines at the IC<sub>25</sub> concentration. The in vivo study revealed that compounds **86a–c** were nontoxic against the CNS of Swiss mice, showing the highest biological activity, and compound **86c** showed significant anodyne activity due to blocking of the cell cycle at the G<sub>2</sub>/M phase and stimulation of apoptosis. The authors assumed that the study of compounds (**86a–c**) as an anticancer drug could be linked with the cyclooxygenase-2 (COX-2) enzyme, which is associated with apoptosis, angiogenesis and metastasis



product	R <sub>1</sub>	R <sub>2</sub>	Time	Yield
<b>a</b>	p-flouro	-ethyl	3.5h	83%
<b>b</b>	p-chloro	-ethyl	3.5h	81%
<b>c</b>	3,4-dimethoxy	-ethyl	3.5h	93%
<b>d</b>	m-bromo	-ethyl	4h	89%
<b>e</b>	p-methoxy	-ethyl	4h	83%
<b>f</b>	p-flouro	-methyl	3.5h	82%
<b>g</b>	p-chloro	-methyl	3h	89%
<b>h</b>	3,4-dimethoxy	-methyl	3.5h	91%
<b>i</b>	m-bromo	-methyl	3.5h	81%
<b>j</b>	p-methoxy	-methyl	4h	80%


**Scheme 70** Synthesis of pyrazolo-oxothiazolidine derivatives **87(a–j)**

**Table 4** Antiproliferative activity of pyrazolo-oxothiazolidine derivatives **87a–j** on A549 (lung cancer) cell line

S. no.	Name of compound	IC <sub>50</sub> on A549 cell line (μg/mL)
1	<b>87a</b>	0.930
2	<b>87e</b>	1.207
3	<b>87f</b>	0.808
4	<b>87g</b>	1.078
5	<b>87h</b>	0.967
6	<b>87j</b>	2.445
7	Sorafenib	3.779

effects in reference cell lines. These results confirmed significant antitumor activity of compounds (**86a–c**).

Yakaiah and coworkers [121] described a proficient one-pot multicomponent synthesis of pyrazolo-oxothiazolidine derivatives **87(a–j)** and evaluated their antiproliferative activity against A549 cell lines. Pyrazolo-oxothiazolidine derivatives were obtained in high yields (91%) from 1-(benzofuran-2-yl)-3-(substituted)-aryl-prop-2-en-1-ones, dialkyl acetylenedicarboxylates and thiosemicarbazide reaction at different reaction conditions and catalyst and 20 mol% of NaOH and ethanol at 80 °C (Scheme 70). For the study of antiproliferative activity of pyrazolo-oxothiazolidine derivatives, the catalytic site of receptors EGFR 14 and VEGFR2 were used, and sorafenib (IC<sub>50</sub>, 3.779 μg/mL) was used as a standard drug. The results of in vitro inhibition showed that the IC<sub>50</sub> value of compounds **87a** (0.930 μg/mL),




**Scheme 71** Synthesis of thiazolidine derivatives **88a–d**


**87e** (1.207  $\mu\text{g/mL}$ ), **87f** (0.808  $\mu\text{g/mL}$ ), **87g** (1.078  $\mu\text{g/mL}$ ), **87h** (0.967  $\mu\text{g/mL}$ ) and **87j** (2.445  $\mu\text{g/mL}$ ) displayed good potency (Table 4).

Rodrigues and his group [122] synthesized benzylidene-2,4-thiazolidinedione derivatives **88(a–d)** which were found to display selective cytotoxic and genotoxic activity and were screened on the NCI-H292 (human lung carcinoma), MCF-7 (breast adenocarcinoma), HEP-2 (cervix carcinoma), K562 (leukemia) and HT29 (colon adenocarcinoma) cell lines using MTT assay and non-tumor cells (human peripheral blood mononuclear cells, PBMC) using the alamarBlue assay. The aldehydes reacted with thiourea and monochloroacetic acid in an aqueous medium to produce thiazolidine-2,4-dione derivatives **88(a–d)** (Scheme 71). The highest genotoxicity and cytotoxicity was found for compound 5-(2-bromo-5-methoxybenzylidene)-thiazolidine-2,4-dione (**88d**) with the lowest IC<sub>50</sub> value of 1.26  $\mu\text{g/mL}$  for NCI-H292 which did not affect normal cells.

Synthesis, cytotoxicity and anticancer activity of pyridine-thiazolidinones were reported by Ansari et al. [123]. To obtain unique human CAIX inhibitors, the synthesis was carried out with the mixture of 3-(furan-2-ylmethyl)-2-(phenylimino)-1,3-thiazolidin-4-one, aldehydes and hexahydropyridine using ethanol (Scheme 72). The cell cytotoxicity was identified by standard MTT assay and CAIX (PDB ID: 3IAI) was used for molecular docking study. The derivatives of **89** showed low to moderate inhibition against CAIX. Compounds **89** (**c**, **d**, **f**, **g**, **j**, **m**, **n** and **q**) (IC<sub>50</sub> values = 50.92  $\mu\text{M}$ , 57.31  $\mu\text{M}$ , 40.41  $\mu\text{M}$ , 40.18  $\mu\text{M}$ , 63.11  $\mu\text{M}$ , 60.92  $\mu\text{M}$ , 38.40  $\mu\text{M}$  and 43.52  $\mu\text{M}$ , respectively) containing alkoxy and chloro groups displayed low inhibitory activity, and compounds **89** (**l**, **o**, **r**, **s**) (IC<sub>50</sub> values = 20.92  $\mu\text{M}$ , 16.68  $\mu\text{M}$ , 6.64  $\mu\text{M}$  and 10.04  $\mu\text{M}$ , respectively) having a disubstituted methoxy group or heterocyclic substitution showed good inhibitory effect. Compounds **89e**, **h** (1.61  $\mu\text{M}$ ), **k** (1.84  $\mu\text{M}$ ), and **r** (6.64  $\mu\text{M}$ ) with a nitro or hydroxyl group exhibited outstanding inhibitory activity. It was concluded that inhibition of CAIX not only depends on substituents but also on the molecular skeleton. HEK cell lines were used as reference for cytotoxicity. All compounds gave satisfactory activity for cancer against MCF-7 and HepG2 cell lines. Compounds **89h** and **89k** showed the most promising activity for cancer treatment.




**Scheme 72** Synthesis of pyridine-thiazolidinone derivatives **89(a-r)**



**Scheme 73** Synthesis of thiazolidine derivatives **90(a-x)**


The synthesis and anticancer activity of various thiazolidine-2,4-dione derivatives were evaluated by Asati et al. [124]. The thiazolidine derivatives were obtained from 4-((2,4-dioxothiazolidin-5-ylidene)methyl)benzohydrazide and aliphatic or aromatic acids in the presence of POCl<sub>3</sub> (Scheme 73) and showed anticancer activity



**Scheme 74** Synthesis of novel 4-hydroxy-thiazolidine-2-thione derivatives **91(a-z)**

against MCF-7 with the SRB method. The H-bonding interaction of the oxygen atom at the second and fourth position of thiazolidinedione derivatives with ASP186 and LYS67, respectively, played a vital role in the activity and nature of the substituents, which was responsible for the activity. Among the tested compounds, compound **90x** demonstrated the most marked effect in the MCF-7 cell lines (GI50 value 0.004  $\mu\text{M}$ ) and displayed a  $-6.68$  docking score against PIM-1 kinase. Compounds **90c** (GI50 values 0.028), **90d** (0.012), **90e** (0.097), **90f** (0.055), **90h** (0.087), **90i** (0.087), **90o** (0.031) and **90t** (0.019) showed potent activity, while compounds **90** (**g**, **i-k**, **m**, **q**, **r**, **s**, **u** and **v**) showed intermediate inhibition effect. When EWGs like Cl, Br and I were used, the activity increased, and the activity decreased in the presence of EDGs like 2-methyl. The SAR studies indicated that the presence of a phenyl ring was crucial for anticancer activity.

A range of 4-hydroxy-thiazolidine-2-thione derivatives **91a-91z** were synthesized and screened for antiproliferative activity by Li and coworkers [125]. For the study of the 4-hydroxy-thiazolidine-2-thione moiety as a drug, it was divided into two subunits, subunit A (the phenyl group) and subunit B (the pyridin-3-ylmethyl moiety), on the basis of their structure. The modification in subunit A was carried out by the reaction of substituted sulfonyl chlorides and 4-aminoacetophenone, and they formed intermediates which further reacted with phenyltrimethylammonium tribromide, pyridin-3-ylmethanamine and carbon disulfide (Scheme 74). This compound was more potent as pyruvate kinase M2 isoform (PKM2) activators. The SARs study using fluorescent PK-LDH coupled assay showed that the electronic and steric effect of substituents at the benzene ring affected activation activity of PKM2. Compounds **91t** and **91y** (AC50 value 0.52  $\mu\text{M}$ , 0.74  $\mu\text{M}$  respectively) showed higher potency than other derivatives (AC50=2.96  $\mu\text{M}$ ). The EWG (**91h-91m**), multi-substituents (**91d** and **91e**) and large groups which showed steric hindrance (**91n-91p**) on the benzene ring deactivated PKM2, and when the ring was substituted with  $-\text{CH}_3$  and  $-\text{OCH}_3$  groups at the *meta* and *para* positions, the activity was decreased, whereas a methyl group at the ortho position at nanomolar concentration increased the activity. The PKM2 activity was affected when the benzene ring




**Scheme 75** Synthesis of 1,3-thiazolidin-4-one compounds **94** and **95**

**Table 5** Cytotoxicity and anticancer activity of some active compounds in selected cancer cell lines [126]

Compound	% Proliferation (at 10 $\mu\text{M}$ dose)				
	NIH3T3	A549	HeLa	HT-29	MCF-7
<b>92</b>	78.12	89.29	78.77	67.71	91.61
<b>93</b>	92.01	76.26	80.89	61.08	79.60
<b>94</b>	98.19	74.46	64.18	81.81	97.97

was replaced with different rings (**91q**, **91r**, **91z**), replacement of the N-containing bicyclic ring with other rings, and length of carbon linker between the 4-hydroxythiazolidine-2-thione framework and the pyridine framework due to hydrogen bonding interaction with PKM2. The previous study showed that **91w** arrested the G2/M phase of the cell cycle in HCT116 cell lines. Here, compound **91w** ( $\text{IC}_{50}$  values 0.46–0.81  $\mu\text{M}$ ) was the most active antitumor agent against HCT116, HeLa, H1299 and PC3 cell lines.

Kulabaş et al. [126] synthesized 4-thiazolidinone derivatives from thiourea and ethyl bromoacetate and screened them for anticancer and antiviral activity. Enterovirus, Yellow fever virus, Murine norovirus and Chikungunya virus strains were used for screening of antiviral potency. 4-Thiazolidinone derivatives were obtained in two different ways; firstly, cyclization of chloroacetamide with  $\text{NH}_4\text{SCN}$ , and secondly, cyclization of thiourea and ethyl bromoacetate with sodium acetate. In this method, five tautomeric forms were obtained (Scheme 75). All synthesized compounds have  $\text{EC}_{50}$  value higher than 0.3  $\mu\text{M}$ . The anticancer activity was evaluated against K562, MCF-7, A549, PC-3, HT-29, HeLa and SJSA1 cell lines at a dose of 10  $\mu\text{M}$ . Compounds **92** and **93** showed significant inhibition effect, i.e. 32.29% inhibition in HT29 and 35.82% inhibition in HeLa cell lines, respectively. Compound **94** was identified as the most active substance (38.92% inhibition vs. HT-29 and 35.96% inhibition vs. SJSA1) and has a high survival rate of 92.01% from NIH3T3 cell lines (Table 5).




**Scheme 76** Synthesis of 4-thiazolidinone derivatives **96**, **97** and **98** and their most biologically active compounds

Bataille and coworkers [127] synthesized novel 4-thiazolidinone derivatives and evaluated their anticancer activity for cancer in blood and lymph tissue via inhibition of the PIM kinase family by differential scanning fluorimetry (DSF). The *in vitro* antiproliferative activity was evaluated in two cancer cell lines (MV4-11 and K562) against selected inhibitors. They used mainly two approaches; Firstly, they synthesized fused tricyclic series through hydrolysis followed by conjugate addition, which showed significant improvement in both solubility and metabolic stability. Another approach showed improvement in metabolic activity by addition of pseudothiohydantoin in place of the rhodanine head group. A compound of series **96** was formed by Knoevenagel condensation of carbonyl compounds and rhodanine using piperidine in EtOH (Scheme 76). The other derivatives were synthesized by Suzuki–Miyaura coupling, using  $\text{RB(OH)}_2$  and  $\text{Pd(PPh}_3)_4$  in  $\text{Na}_2\text{CO}_3$ , which further underwent Knoevenagel condensation with rhodanine using piperidine as catalyst to obtain tricyclic compounds. The compounds were divided into 11 classes on the basis of their structure. These series possessed better selectivity for pan-PIM kinases than other kinases. All tested compounds displayed good activity, and derivative **98b** exhibited high activity against the K562 cell line, with an  $\text{IC}_{50}$  value of 0.751M. Compound **97a** has a phenyl group, and displayed a 90-fold increase in activity, with an  $\text{IC}_{50}$  value of  $6.7 \pm 3.1$  nM, and the *in silico* study revealed that their rhodanine head group showed H-bonding interaction with water which was connected with the Lys67 residue, and this interaction was found to be sandwich-like interaction between the products and the lipophilic area of the PIM binding pocket. The SAR study indicated that an electronic effect did not play a significant role in inhibition activity. Compound **98a** containing a sulfonamide group showed excellent PIM1 inhibitor activity ( $\text{IC}_{50}$   $25 \pm 4$  nM) and also provided better kinetic solubility than other compounds.

Sharma and coworkers [128] synthesized novel benzimidazole nucleus-linked thiazolidinedione hybrids and screened them as potential cytotoxic and apoptosis-inducing agents against human cancer cell lines, prostate (PC-3 and DU-145), breast (MDA-MB-231), A549 and MCF10A using MTT assay, and 5-FU was used as the





a-c:NR<sub>1</sub>R<sub>2</sub> = pyrrolidine, R<sub>3</sub> = methyl, ethyl, isopropyl

d-f:NR<sub>1</sub>R<sub>2</sub> = piperidine, R<sub>3</sub> = methyl, ethyl, isopropyl

g-i:NR<sub>1</sub>R<sub>2</sub> = morpholine, R<sub>3</sub> = methyl, ethyl, isopropyl

j-l:NR<sub>1</sub>R<sub>2</sub> = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline,  
R<sub>3</sub> = methyl, ethyl, isopropyl

m-o:NR<sub>1</sub>R<sub>2</sub> = 2,6-dimethylmorpholine, R<sub>3</sub> = methyl, ethyl,  
isopropyl

p-q:NR<sub>1</sub>R<sub>2</sub> = 4-phenylthiazole, R<sub>3</sub> = methyl, ethyl


r-t:NR<sub>1</sub>R<sub>2</sub> = 5-(tert-butyl)isoxazole, R<sub>3</sub> = methyl, ethyl,  
isopropyl

**Scheme 77** Synthesis of (Z)-5-[(1-alkyl-1H-benzo[d]imidazole-2-yl)methylene]-3-(2-oxoethyl)thiazolidine-2,4-dione derivatives **99(a-t)**


**Table 6** IC<sub>50</sub> values (μM) of the most active compounds against selected human cancer cell lines [128]

Compound	PC-3	DU-145	MDA-MB-231	A549
<b>99j</b>	41.10 ± 3.08	37.52 ± 1.45	36.03 ± 1.53	13.35 ± 1.26
<b>99p</b>	39.87 ± 3.16	31.41 ± 1.52	29.18 ± 0.9	11.46 ± 1.46
<b>99r</b>	> 50	31.36 ± 1.12	33.82 ± 1.37	15.30 ± 0.92
5-FU	45.32 ± 2.08	40.58 ± 1.83	35.98 ± 1.52	30.47 ± 1.09

**Scheme 78** Synthesis of 3-(4-bromophenyl)-2-(4-(dimethylamino)phenyl)thiazolidin-4-one (**100e**)



standard drug. Novel benzimidazole-thiazolidinedione hybrids were synthesized by Knoevenagel condensation in substituted thiazolidinedione and 1-alkyl-1H-benzo[d]imidazole-2-carbaldehydes in moderate to high yields. The pathway of the reaction is outlined in Scheme 77. All compounds have good growth inhibition against the tested cancer cell lines. Compounds **99j**, **99p** and **99r** showed good antitumor effects with IC<sub>50</sub> ≤ 15 μM against A549 cell lines and were safe to MCF10A (Table 6). The contact of compound **99p** with the A549 cell showed arrest of the G2/M phase of the cell cycle, inhibited in vitro cell migration (using wound-healing assay) via disruption of F-actin assembly and decreased F-actin extension, and apoptotic activity such as cell contraction, cell wall distortion and decreased viable cell numbers. For induction of apoptosis acridine orange-ethidium bromide (AO-EB), annexin V-FITC/propidium iodide staining, DAPI, MitoSOX and rhodamine-123 assays were used in A549 cells for compound **99p**. According to SAR studies, the




**Scheme 79** Synthesis of the chromonylthiazolidine derivatives **101(a–i)**

substitution on the head position gave high bioactive compounds as compared to tail substitution.

Kumar and coworkers [129] developed a simple and direct synthesis of 4-thiazolidinone derivatives in the presence of propylphosphonic anhydride (T3P)-DMSO media as a cyclodehydrating agent and evaluated their cytotoxicity both in vitro and in vivo against leukemic cell lines (Reh and Nalm6). 4-Thiazolidine derivatives **100(a–j)** were produced from primary and secondary alcohols and aryl amines using T3P-DMSO via one-pot synthesis at high yields (Scheme 78). The relative study displayed that the compounds exhibited better activity on Reh cell lines than Nalm6 cell lines. Among all tested compounds, 3-(4-bromophenyl)-2-(4-(dimethylamino)phenyl)thiazolidin-4-one (**100e**) showed potent activity against Reh cells and Nalm6 cells with IC<sub>50</sub> values of 11.9  $\mu$ M and 13.5  $\mu$ M, respectively. The cell cycle analysis showed that **100e** was able to aggregate cells in cell cycle subG1 phase, and also decreased the mitochondrial membrane potential and increased cell death in tested cell lines via apoptotic cell death. The EAC tumor model in a Swiss albino mouse revealed a significant reduction in tumor cell volume and did not affect the other organs and cells.


Anh and colleagues [130] synthesized a new range of hybrid thiazolidine compounds attached with the naturally occurring paeonol. The compounds exhibited selective anticancer activity against eight cancer cell lines, HepG2, acute promyeloid leukemia, KB, LU-1 (human lung cancer), LLC, SW480 (colon adenocarcinoma), hormone-dependent prostate cancer and MCF7 (breast cancer) using MTT assay. The predicted reaction mechanism for this protocol was decoded as paeonol reacting with dimethylformamide (DMF) via Vilsmeier–Haack reaction to afford 3-formyl-7-methoxychromone, which underwent Knoevenagel condensation with 2,4-thiazolidinedione using base catalyst (piperidine or sodium acetate), to give chromonylthiazolidines **101(a–i)** (Scheme 79). All semi-synthesized compounds showed low cytotoxic effect against all cell lines; however, this cytotoxic effect was highly selective. Compounds **101a** and **101b** showed highly selective cytotoxicity in this series against KB (IC<sub>50</sub> 44.1  $\pm$  3.6  $\mu$ g/mL) and MCF7 (IC<sub>50</sub> 32.8  $\pm$  1.4  $\mu$ g/mL) cell lines, respectively. The advantages of this research are the use of easily available, affordable and natural starting material paeonol and hybrid chromonylthiazolidines as selective antitumor agents.

A series of novel hybrid compounds 2, 4-thiazolidinedione incorporated pyrazole were produced and introduced for anticancer activity by Kumar and coworkers [131]. 3-(Substituted aryl)-1-phenyl-1*H*-pyrazolyl-2,4-thiazolidinediones



Ar: **a** = benzene, **b** = 4-chloro benzene, **c** = 4-methyl benzene, **d** = 4-methoxy benzene, **e** = 2-methoxy benzene, **f** = 4-hydroxy benzene, **g** = 2-hydroxy benzene, **h** = naphthyl


**Scheme 80** Synthesis of 3-(substituted aryl)-1-phenyl-1H-pyrazole-2,4-thiazolidinones derivatives **102(a-h)**



**Scheme 81** Synthesis of 5-(4-substituted)-3-[(4-substituted)amino]methyl]-1,3-thiazolidine-2,4-diones **103(a-e)**

**102(a-h)** were prepared by the cyclization of substituted phenyl hydrazones via Vilsmeier–Hack reaction followed by condensation with 2, 4-thiazolidinedione employing piperidine as a catalyst in glacial acetic acid (Scheme 80). The synthesized moieties were tested for their anticancer potency against three cancer cell lines, A549, MCF-7 and DU145 using MTT based cytotoxic assay and Doxil as a reference drug. Among all the hybrids, compound **102b** emerged as a highly active cytotoxic agent for all three cancer lines, A549, MCF-7, DU145 (IC<sub>50</sub> values 4.63, 1.32 and 5.25 μg) respectively. Compounds **102c** and **102h** showed significant activity against A549 and MCF-7 with IC<sub>50</sub> values ranging from 4.44 to 9.16 μg.

The series of substituted thiazolidinediones have been prepared and their anticancer activity and cytotoxicity were evaluated *in vitro* by Akshaya et al. [132] 5-(4-substituted)-3-[(4-substituted) amino]methyl]-1,3-thiazolidine-2,4-diones were obtained from reflux of 5-arylidene thiazolidine-2,4diones, formaldehyde and aromatic amine in the presence of methanol. The reaction proceeded via two-step mechanism involving Knoevenagel condensation of thiazolidinediones with aromatic aldehydes using L-tyrosine as a catalyst which further underwent Mannich reaction with aromatic amines and formed Mannich bases (Scheme 81). All derivatives showed good cytotoxic effect on both PPAR-γ using wet lab synthesis and MCF-7 cell lines by MTT assay. The outcomes of SARs revealed




**Scheme 82** Synthesis of fused thiazolidine-2,4-dione derivative **104**

that presence of electron withdrawing groups like bromine, chlorine, fluorine enhanced the activity of drugs. Compounds **103a** and **103b** showed high potency against MCF-7, due to electronegativity of substituents and non-bonding valence electron, whereas presence of electron releasing group decreased activity of product against MCF-7 cell lines.

### 3.3 Anti-inflammatory Activity

Yeh and coworkers [133] synthesized a large panel of thiazolidinedione derivatives and evaluated them for in vitro and in vivo activity against glutaminase gene transcripts such as kidney isoform (KGA), GAC, liver isoform and GAB, and also investigated them in relation to chemical structure, activity and their selectivity. The compounds were synthesized via multistep synthesis of diketone, amine and *p*-toluenesulfonic acid. The intermediate obtained was further reacted with  $\text{POCl}_3$  in DMF to obtain bromoarene which was refluxed with corresponding arylboronic acid, sodium bicarbonate and  $\text{Pd}(\text{PPh}_3)_4$  as a catalyst in the mixture of ethanol/water/DME to form an adduct, which reacted with thiazolidinedione, AcOH and piperidine using toluene to produce compound **104**. Most of the compounds exhibited high inhibition against KGA and GAC and good inhibition against GAB. The synthesized compounds inhibited cell growth, glutamate production, clonogenicity and decreased the size of tumor of xenografted human pancreatic AsPC-1 carcinoma cells in mice (Scheme 82).

Ashour and coworkers [134] synthesized substituted thiazolidinones possessing pyrazolyl benzenesulfonamides and evaluated them as anti-inflammatory active drugs by applying formalin-induced paw edema bioassay, and the analgesic activity was studied from the rat tail withdrawal technique, using diclofenac sodium as a standard drug. For the preparation of 4-[5-amino-4[[*(2E)*-2-[(*5Z*)-5-substituted-4-oxo-1,3-thiazolidin-2-ylidene]hydrazinyl]carbonyl]-1*H*-pyrazol-1-yl]benzenesulfonamides (**105**, **106**), firstly, ethyl 5-amino-1-(4-sulfamoylphenyl)-1*H*-pyrazole-4-carboxylate and



Reagents and Conditions: (i)  $\text{ClCOCH}_2\text{Cl}$ /dry DMF/RT; (ii)  $\text{NH}_4\text{SCN}$ /ethanol/reflux;


(iii)  $\text{C}_6\text{H}_5\text{CHO}$  or  $4\text{-ClC}_6\text{H}_4\text{CHO}$ /DMF/abs. ethanol/piperidine/reflux;

(iv) 3-aryl-1-phenyl-1H-pyrazole-4-carboxaldehyde/DMF/ abs. ethanol/piperidine/reflux

**Scheme 83** Synthesis of pyrazolylbenzenesulfonamides-linked thiazolidinones **105** and **106**


**Fig. 8** (*S\*,S\*\**)-**107**

3,5-Dichloro-4-((*S*)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((*S*)-3-(3-dimethylcarbamoyl)-phenylsulfonyl)thiazolidine-2-carboxyloxy)ethyl)pyridine 1-oxide as PDE4 inhibitor



chloroacetyl chloride were refluxed in dry DMF, which cyclized with ammonium thiocyanate in ethanol to produce an adduct in high yields and purity, followed by Knoevenagel condensation with aldehydes or 3-aryl-1-phenyl-1H-pyrazole-4-carboxaldehydes and piperidine in dry DMF/absolute EtOH mixture (Scheme 83). All compounds showed effective anti-inflammatory and analgesic activity. Compounds **105a**, **105b** and **106a** (45–48%) displayed superior activity than the diclofenac sodium (38%), and compounds **105a** and **106a** (22–42%) exhibited high activity as compared to the reference drug (16%). All active compounds showed minimal ulcerogenic effects. According to SAR study, after 4-h intervals, the substituted ylidene derivatives (**105b**, **106b**) were more active than the unsubstituted phenyl analogs (**105a**, **106a**). The *in vitro* COX inhibition assay results showed that all thiazolidinones were more selective to COX-2 than COX-1, and the motif **105b** exhibited the maximum potency for both COX-1 and COX-2 (IC<sub>50</sub> values of 4.51  $\mu\text{M}$  and 1.06  $\mu\text{M}$ , respectively).


A novel series of thiazolidinyl esters were produced from benzoic acid ester and screened as potent *in vitro* phosphodiesterase 4 (PDE4) inhibitors, in chronic obstructive pulmonary diseases (COPD) and related inflammatory diseases by Carzaniga et al. [135]. According to the mechanism, initially alcohol coupled with the appropriate thiazolidine-carboxylic acid isomers in EDC and DMAP, which further showed Boc cleavage to obtain corresponding esters, which when sulfonated in pyridine gave final sulfonamide products. Some synthesized compounds reacted



**Scheme 84** Synthesis of 5-arylidene-4-thiazolidinone derivatives **108–111(a–d)**

with amine in CDI and DMF to prepare appropriate amides. Compounds (*S*<sup>\*</sup>,*S*<sup>\*\*</sup>)-**107** demonstrated ideal in vitro ADME and pharmacological properties with minimum risk of side effects, and these were highly effective in asthma and pulmonary inflammation (Fig. 8).


Novel thiazolidinone derivatives were designed and produced, and their potency evaluated against diabetes mellitus by Maccari and colleagues [136]. Different hydroxybenzaldehydes, 2-chloroacetamide and acetonitrile were refluxed in potassium carbonate to afford 2-(formylaryloxy)acetamides. The Knoevenagel condensation of 2,4-thiazolidinedione and arylaldehydes provided **108(a–d)**, whereas in different conditions, **110(a–d)** were obtained. Pure 2-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]phenoxy] acetamides and (5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)acetic acids were obtained by the reaction of 2-thioxo-4-thiazolidinone and (4-oxo-2-thioxothiazolidin-3-yl)acetic acid, respectively, with aldehydes by refluxing in a mixture of glacial acetic acid and sodium acetate (Scheme 84). The synthesized compounds showed anti-inflammatory activity for diabetes mellitus and other diseases via inhibited aldose reductase (AR) enzyme. The in vitro inhibition study displayed that compounds **108–111** exhibited good activity against reference drugs sorbinil and epalrestat. Compounds (5-arylidene-2,4-dioxothiazolidin-3-yl)acetic acids **110(a–d)** and corresponding 2-thioxo isosteres **111(a–d)** proved to be the most potent for AR inhibition. The SAR study displayed that compounds **108a**, **108c**, **109a** and **109c** were more potent than their relative *para*-substituted compounds **97b**, **97d**, **98b** and **98d**, and the presence of the *m*-methoxy group or *p*-carboxymethoxy group induced inhibition of AR enzyme. Some compounds also reduced both NF-κB activation and iNOS expression. The binding interaction between final compounds and the active site of AR was investigated by molecular docking study. The enzymatic inhibition results revealed that the fundamental 2-thioxo-4-thiazolidinone ring (**109a–d** and **111a–d**) showed more significant interaction than the isosteric 2,4-thiazolidinedione ring (**108a–d** and **110a–d**).



**Scheme 85** Synthesis of ferrocene carboxaldehyde thiazolidine derivatives **112–114**

### 3.4 Antiparasitic Activity


Oderinlo and coworkers [137] synthesized new thiazolidinedione derivatives possessing organometallic ferrocene and evaluated them for antiparasitic activity. Ferrocene-containing derivatives **112(a–d)** and **114** were prepared by ferrocene carboxaldehyde, thiazolidinedione derivatives or 2-(phenylimino)thiazolidin-4-ones using piperidine in ethanol, whereas derivatives **113(a–b)** were prepared by solution of (Z)-5-((ferrocenyl)methylene)-2,4-dioxothiazolidin-3-yl)acetic acid and 1-methylpiperazine or phenylpiperazine with dry DMF using EDC·HCl, HOBT·H<sub>2</sub>O and DIPEA (Scheme 85). All compounds were screened in vitro for antitrypanosomal activity against *Trypanosoma brucei brucei* 427 trypomastigotes, antiplasmodial activity against the chloroquine-resistant Dd2 strain of *P. falciparum* malaria parasite and cytotoxicity against the HeLa cell lines. Pentamidine (PMD), CQ and EMT were used as standard drugs. By the result of growth inhibition assay, it was concluded that the synthesized compounds exhibited higher selectivity against *T. b. brucei* than *P. falciparum*, and compounds **113a** and **113b** displayed high antitrypanosomal activity with IC<sub>50</sub> values of 1.94 μM and 3.31 μM, respectively, when compared to TZD-4 (IC<sub>50</sub>=7.51 μM). In case of *P. falciparum*, none of the molecules gave better potency compared to TZD-4. All tested compounds showed non-toxicity and > 90% HeLa cell viability, which confirmed the specificity of compounds against protozoan parasites.



**Scheme 86** Synthesis of quinoline–thiazolidinone hybrids containing arylidene derivatives **115(a–r)**

A series of quinoline–thiazolidinone hybrids containing arylidene derivatives was developed as antimalarial agents via *in vitro*, *in vivo* and *in silico* study by Jain and coworkers [138]. For the synthesis of novel compounds, firstly, a mixture of 2-hydrazino-4-methylquinoline reacted with various aromatic aldehydes in glacial acetic acid, and refluxed with mercaptoacetic acid using anhydrous ZnCl<sub>2</sub> in 1,4 dioxane to obtain respective thiazolidinones, which reacted with aryl aldehyde in glacial acetic acid and sodium acetate and produced **115a–e** in good yields (Scheme 86). All the effective compounds were evaluated by *in vitro* schizont maturation inhibition (SMI) assay against chloroquine-sensitive strain 3D7 and chloroquine-resistant strain RKL9 strain of *Plasmodium falciparum*. Compound **115g** displayed the most potent activity against both 3D7 and RKL9 strains with EC<sub>50</sub> (3D7/RKL-9) values of 0.423/0.824 mg/mL via *in vitro* study and also showed the highest parasitemia inhibition (73.38%) against *P. berghei* from *in vivo* study. Among all compounds, **115b**, **115e**, **115g**, **115j** and **115n** displayed significant activity from *in vitro* study and *in vivo* study against *P. berghei* in Swiss albino mice. The SAR studies concluded that the presence of a *p*-chloro group in one phenyl ring along with a *p*-methyl group in another ring gave the most potent derivative **115g** among the series. For the inhibition activity, the *p*-methyl group was more potent than the *p*-methoxy group at the phenyl ring, and the size of the ring also affected the activity of compounds. The *in silico* study explained the possible pathway for antimalarial activity of synthesized compounds, and the docking study proved the synthesized compounds as antimalarial agents.






**Fig. 9** Ligand selections for combinational modifications and some fused thiazolidine derivatives as HIV protease inhibitors **116(a-d)**

### 3.5 Antiviral Activity

HIV-1 RT acts as a prime target for synthesis of inhibitors for HIV/AIDS treatment. The thiazolidine nucleus contains essential pharmacophoric elements like a benzene ring, a nitrogen atom, substitution at C-2 and N-3, lipophilic characters and a biophoric space of various heterocycles around the N-3 position, which is necessary for HIV inhibition. A series of allophenylnorstatine-based peptidomimetics with various P<sub>1</sub>, P<sub>2</sub>, P<sub>3</sub> and P<sub>2</sub>' moieties (Fig. 9) was synthesized and screened as HIV-1 protease inhibitors by Hidaka et al. [139]. All compounds with P<sub>2</sub> tetrahydrofuranylglycine (Thfg) exhibited significant activity against wild-type HIV-1 protease and the virus against lopinavir/ritonavir- or darunavir-resistant strains. Among all derivatives, compound **116d** (KNI-1657) displayed strong activity against the reference strain. Compound **116a** including P<sub>2</sub> (2S, 3'R)-Thfg showed 96% inhibition against HIV-1 protease at 1-nM concentration. Compound **116b** showed 98% inhibition at 60 nM, and **116c** in human serum displayed the most potent inhibition among the series. The derivatives with P<sub>3</sub> modifications including chromonylcarbonyl, benzofurancarboxyl and 7-methoxybenzofurancarboxyl were found to be highly active against HIV protease, whereas selected P<sub>2</sub>' derivatives displayed inhibition activity in a 93–97% range at 1 nM.

### 3.6 Antidiabetic Activity

Wang and colleagues [140] designed and produced a range of novel thiazolidine-dione derivatives and explained their inhibitor activity on alpha glucosidase using acarbose as the standard drug. The desired compounds **117** and **118** were synthesized via the following method: Firstly, phthalimide reacted with HCHO and formed 2-(hydroxymethyl)isoindoline-1,3-dione, which on refluxing with thionyl SOCl<sub>2</sub> afforded 2-(chloromethyl)isoindoline-1,3-dione. The treatment of 2-(chloromethyl)isoindoline-1,3-dione with diverse hydroxyl-substituted aromatic aldehydes using



position of 5-Ethyldene-thiazolidine ring and R group for **117** and **118** ;

**a** = *para*, 2-methoxy, **b** = *para*, 2-ethoxy, **c** = *meta*, H, **d** = *ortho*, H, **e** = *para*, H, **f** = *ortho*, 6-methoxy  
**g** = *para*, 2,6-dimethoxy, **h** = *para*, 2-nitro, **i** = *ortho*, 4-Chloro, **j** = *ortho*, 4-nitro, **k** = *para*, 2-Chloro

X for **117(a-k)** =O; **118(a-k)** =S


**Scheme 87** Synthesis of thiazolidine-2,4-dione derivatives **117** and **118**



R for **a** = H, **b** = CH<sub>3</sub>, **c** = C<sub>2</sub>H<sub>5</sub>, **d** = Cl, **e** = Br, **f** = F, **g** = NH<sub>2</sub>, **h** = NO<sub>2</sub>

**Scheme 88** Synthesis of substituted bezylideneamino-benzylidene-thiazolidine-2,4-diones **119**

anhydrous K<sub>2</sub>CO<sub>3</sub> in dry acetone provided an adduct, which further underwent Knoevenagel condensation with rhodanine or thiazolidine-2,4-dione using  $\beta$ -alanine. It was previously observed that in the final compounds, a high yield of *Z*-stereoisomer was obtained (Scheme 87). Among all the synthesized derivatives, most compounds were potent inhibitors as compared to the reference drug. Compounds **117k**, **118a**, **118b**, **118e**, **118h** and **118k** have IC<sub>50</sub> values of 20.95  $\pm$  0.21, 16.11  $\pm$  0.19, 7.72  $\pm$  0.16, 7.91  $\pm$  0.17, 6.59  $\pm$  0.15 and 5.44  $\pm$  0.13  $\mu$ M, respectively, which represent their high inhibition activity. Compounds **117(a, b, e, h, j)** and **107(c, g, i, j)** were equipotent to reference drug acarbose. The derivative **118k** with chloro and rhodanine groups at the 2- and 4-positions of the phenyl ring, respectively, exhibited the highest inhibition activity against  $\alpha$ -glucosidase, with an IC<sub>50</sub> value of 5.44  $\pm$  0.13  $\mu$ M. The SAR study showed that substitution of oxygen with sulfur in final compounds displayed remarkable increase in activity. It was also observed that EWGs chloro (**117k**, **118k**) and nitro (**117h**, **118h**) at the *ortho*-position of the phenyl ring increased inhibition against the reference drug than electron-donating substituents ( $-\text{OCH}_3$ ). The binding interaction between the most active compounds and the active site of  $\alpha$ -glucosidase was confirmed by molecular docking studies. In the binding place of  $\alpha$ -glucosidase, compounds changed in “L-shaped” conformation,




**Scheme 89** Synthesis of 5-((3-(aryl)-1-phenyl-1H-pyrazol-4-yl)methylene)-2-(*p*-tolylimino) thiazolidin-4-ones **120(a-g)**

showed hydrogen bond interaction and displayed CH- $\pi$  interactions with the residue of Phe-157, Phe-177 and Phe-300.

Novel substituted benzylideneamino-benzylidene-thiazolidinones were prepared and further studied for their utilization on PPAR- $\gamma$ , hyperglycemia and hypoglycemia for control of diabetes mellitus by Chhajed et al. [141]. Thiazolidinone was reacted with 4-nitrobenzaldehyde using sodium acetate and glacial AcOH to produce (*E*)-5-(4-nitrobenzylidene)thiazolidine-2,4-diones, which on reduction by SnCl<sub>2</sub>, gave (*E*)-5-(4-aminobenzyl)thiazolidine-2,4-dione, which combined with substituted aldehyde in concentrated sulfuric acid to form (*E*)-5-((*E*)-4-((*E*)-4-benzylideneamino)benzylidene)thiazolidine-2,4-diones (Scheme 88). All compounds were tested using glucose uptake assay in 3T3-L6 cell lines with rosiglitazone as a reference drug. Among all tested compounds, **119(a-h)** exhibited strong binding with the PPAR- $\gamma$  binding site, and hyperglycemic control was shown by **119a**, **119b** and **119g**. The SAR study revealed that the activity of the compounds was controlled by the benzylidene moiety's substitution. The activity was increased when a molecule substituted at the *para* position in place of the *meta* position. In the glucose uptake assay, the substituted analog with a methyl group showed 1.9-fold activity, while the ethyl group showed 0.9-fold activity.


Kumar and group [142] developed a novel synthesis of 5-((3-(aryl)-1-phenyl-1H-pyrazol-4-yl)methylene)-2-(*p*-tolylimino)thiazolidin-4-ones **120(a-g)** and evaluated them for in vitro  $\alpha$ -amylase inhibition. The compound **120(a-g)** were obtained in the form of a mixture of *2E,5Z* (37.1–42.0%) and *2Z,5Z* isomer (58.4–62.8%). *p*-Tolyl thiourea and ethyl bromoacetate were reacted to form 2-(*p*-tolylimino)thiazolidin-4-one, that was refluxed with 3-(aryl)-1-phenyl-1H-pyrazole-4-carbaldehyde using piperidine in ethanol to produce desired products **120(a-g)** (Scheme 89). Compound **120a** showed 90.04% inhibition, and the docking studies concluded that interaction between **120a** and human pancreatic alpha-amylase were the same as acarbose.

Patel and coworkers [143] designed a large panel of 5-[4-(substituted) benzylidene]thiazolidine-2,4-diones and screened them for antidiabetic activity by OGTT



Where Ar = 4-COOHC<sub>6</sub>H<sub>4</sub>-, 4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>-, 4-ClC<sub>6</sub>H<sub>4</sub>-, 3-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>-, 4-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>-, C<sub>6</sub>H<sub>5</sub>-, 4-OHC<sub>6</sub>H<sub>4</sub>-, 2-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>-, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>-, 4-FC<sub>6</sub>H<sub>4</sub>-


**Scheme 90** Synthesis of 5-[4-(substituted) benzylidene]thiazolidine-2,4-diones **121(a-j)**




**Scheme 91** Synthesis of substituted 5-{[2-(4-fluorobenzyl)-6-arylimidazo[2,1-b] [1,3,4] thiadiazol-5-yl]methylene}thiazolidine-2,4-diones **122(a-d)**

methods using pioglitazone as reference on male Wistar rats. The compounds were synthesized via 1,3 dipolar cycloaddition using chloroacetic acid and thiourea and water, which further underwent Knoevenagel condensation with 4-Cl benzaldehyde to furnish 5-(4-chlorobenzylidene)-2,4-thiazolidinedione. Thiazolidinedione was refluxed with primary aniline using acetonitrile and K<sub>2</sub>CO<sub>3</sub> in microwave irradiation of 200 W to produce 5-[4-(substituted) benzylidene]thiazolidine-2,4-diones **121(a-j)** (Scheme 90). The thiazolidinedione ring showed strong interaction with the binding site of the receptors and showed more potency for antidiabetic activity. The presence of a lipophilic group and EDG at the second and fourth position of the aromatic ring enhanced their activity. Compound **121e** displayed high antidiabetic activity, whereas **121g** and **121h** showed moderate antidiabetic activity.

Badiger et al. [144] synthesized 5-{[2-(4-fluorobenzyl)-6-arylimidazo[2,1-b] [1,3,4] thiadiazol-5-yl]methylene}thiazolidine-2,4-diones and tested them in male Wistar rats for their antidiabetic activity (in vivo hypoglycemic and hypolipidemic activity). Imidazo[2,1-b] [1,3,4] thiadiazoles underwent Vilsmeier–Haack reaction and formed imidazo[2,1-b] [1,3,4] thiadiazole-5-carbaldehydes. The mechanism involved the reaction of 2-amino-1,3,4-thiadiazole and  $\alpha$ -haloketones (phenacylbromides) using dry ethanol to give products that were neutralized with the help of aqueous sodium carbonate solution, and the respective free bases imidazo[2,1-b] [1,3,4] thiadiazoles were obtained in high yields, which further displayed Vilsmeier–Haack reaction to give imidazo[2,1-b] [1,3,4] thiadiazole-5-carbaldehydes which further underwent Knoevenagel condensation with thiazolidinone in




**Scheme 92** Synthesis of aryl/alkylsulfonyloxy-5-(3-methoxybenzylidene)thiazolidine-2,4-diones **123(a–j)**



**Scheme 93** Synthesis of 1,3-thiazolidine-2,4-dione derivatives **124(a, b)**

piperidine to yield the targeted products (Scheme 91). Compounds **122c** and **122d** exhibited good hypoglycemic and hypolipidemic activity.

Mahapatra and coworkers [145] reported the fragment-based synthesis of aryl/alkylsulfonyloxy-5-(3-methoxybenzylidene)thiazolidine-2,4-dione derivatives and evaluated their biological activity for inhibition of PTP1B and anti-hyperglycemic activity. Thiazolidinones were formed by condensation of thiourea and chloroacetic acid in concentrated  $\text{H}_2\text{SO}_4$ , and consequently, aryl/alkylsulfonate esters were obtained by *o*-sulfonylation of 4-hydroxy-3-methoxybenzaldehyde in basic medium followed by Knoevenagel condensation, and TZD and aryl/alkylsulfonate esters furnished the final products, aryl/alkylsulfonyloxy-5-(3-methoxybenzylidene)thiazolidine-2,4-diones **123(a–j)** (Scheme 92). The *in silico* study revealed that compounds **123b** and **123e** interacted with both catalyst active sites and other aryl phosphate binding sites and also concluded that H-bonding interaction was absent. The SAR study explained that the presence of phenyl/methyl sulfonate enhanced their activity as compared to other bulky substituents, and the larger arylidene motif displayed better inhibition. Compounds **123b** (IC<sub>50</sub> value 7.31) and **123e** (IC<sub>50</sub> value 8.73) were potent inhibitors for *in vitro* PTP1B activity and *in vivo* anti-hyperglycemic activity. Compounds **123e** and **123i** were also good PPAR $\gamma$  agonists, insulin sensitizers and PTP1B inhibitors, and all the newly synthesized compounds showed potent activity for diabetes.




**Scheme 94** Synthesis of theophyllinyl-acetamido-thiazolidin-4-one derivatives **125(a–k)**

Alemán-González-Duhart and coworkers [146] designed a new synthetic approach to synthesize thiazolidinedione (TZD) derivatives **124a** and **124b** and tested them on the healthy animals for their nontoxic usage. Compound **124b** was synthesized by 1,3-thiazolidine-2,4-dione and salicylaldehyde in solvent-free conditions at 120 °C, and **124a** was prepared by 1,3-thiazolidine-2,4-dione and 3-chloro-2-fluorobenzaldehyde in water at 145 °C (Scheme 93). The authors investigated that the existence of EW heteroatom on aromatic ring, showed better interaction due to hydrogen bonding between the TZD head and binding site of LBD of PPAR $\gamma$ . Both compounds showed activity similar to other reported thiazolidinediones (rosiglitazone, pioglitazone and troglitazone).

### 3.7 Antioxidant Activity

Constantin et al. [147] developed a novel, selective, nontoxic synthesis of thiazolidine-4-one derivatives containing a xanthine structure and evaluated them for antioxidant and antidiabetic activity. Initially, theophylline (1,3-dimethylxanthine) reacted with sodium methoxide and furnished the salt, which combined with ethyl chloroacetate and gave theophylline ethyl acetate. The condensation of theophylline ethyl acetate with hydrazine hydrate led to corresponding hydrazone, which when refluxed with various aromatic aldehydes, theophyllineacetamido-hydrazone derivatives were obtained and further cyclized with mercaptoacetic acid to produce theophyllinyl-acetamido-thiazolidin-4-one derivatives **125(a–k)** (Scheme 94). The *in vitro* antioxidant activity was done using DPPH and ABTS radical scavenging assay and phosphomolybdenum reducing antioxidant power assays. Among all synthesized compounds, **125f**, **125d**, **125c** and **125k** exhibited good activity for antiradical scavenging, and **125c** and **125k** displayed potent activity in phosphomolybdenum reducing antioxidant power. The radical scavenging activity was enhanced in the presence of methyl, methoxy and halogens (fluoro, chloro) substituents at the *para* position of the phenyl ring in final compounds.


Secci et al. [148] reported the design and synthesis of 36 new thiazolidinone derivatives and evaluated them as potent antioxidants; the compounds also displayed chelating properties. For *in vitro* antifungal activity, all synthesized compounds were screened against six topical drugs of *Candida* spp. (*C. glabrata*, *C. tropicalis*,



Ar = substituted phenyl				
<i>o</i> -nitro (A)	A1	A2	A3	A4
<i>m</i> -nitro (B)	B1	B2	B3	B4
<i>o</i> -fluoro (C)	C1	C2	C3	C4
<i>m</i> -fluoro (D)	D1	D2	D3	D4
<i>p</i> -fluoro (E)	E1	E2	E3	E4
<i>o</i> -chloro (F)	F1	F2	F3	F4
<i>m</i> -chloro (G)	G1	G2	G3	G4
<i>p</i> -chloro (H)	H1	H2	H3	H4
<i>p</i> -amino (I)	I1	I2	I3	I4


**Scheme 95** Synthesis of *N*-substituted thiazolidinone derivatives **126(A–I)** series

*C. albicans*, *C. krusei*, *C. parapsilosis* and *C. sakè*) and reference drugs (fluconazole, clotrimazole, ketoconazole, amphotericin B, miconazole and tioconazole) using broth microdilution method. Carbonyl compounds and thiosemicarbazide reacted in ethanol and acetic acid to form thiosemicarbazone, which underwent cyclization with ethyl bromoacetate using sodium acetate in methanol to produce 1,3-thiazolidine-4-one derivatives **126G** (**1** and **2**). The resulting compounds were refluxed with 2-/3-/4-chloro and fluorobenzyl bromide and 2-/3-nitrobenzyl bromide using anhydrous acetone and potassium carbonate to prepare *N*-substituted thiazolidinone derivatives **126(A–H)**. *p*-Nitrobenzyl-*N*-substituted thiazolidinone derivatives reacted with sodium dithionite in DMF in basic aqueous solution which resulted in synthesis of 4-aminobenzyl derivatives **126I** (Scheme 95). Compound **126G3** was the most active against all tested fungal species, due to the substitution of the benzyl group with -Cl at the *meta* position with an MIC value of 2 µg/mL. Compound **126B1** also had the same effect against all species, except *C. parapsilosis*. Compounds **126(A3, C3, D3 and E3)** presented moderate activity (MICs = 2 µg/



Where R: H, 4-OH, 3,5-t butyl, 4-N(CH<sub>3</sub>)<sub>2</sub>, 2-Br, 4-Cl, 3-NO<sub>2</sub>, 4-NO<sub>2</sub>, 4-OCH<sub>3</sub>, 4-CH<sub>3</sub>

**Scheme 96** Synthesis of 4-chloro-*N*-(2-(substituted-phenyl)-4-oxothiazolidin-3-yl)-2-phenoxybenzamide (BZD) derivatives **127(a–j)**



Ar = benzene, 2-Cl benzene, 3-Cl benzene, 4-Cl benzene, 4-F benzene, 4-OH benzene, 4-OCH<sub>3</sub> benzene, 3,4-OCH<sub>3</sub> benzene, 3,4,5-OCH<sub>3</sub> benzene, 3-H-indole.

**Scheme 97** Synthesis of thiazolidine-benzamide derivatives **128(a–j)**


mL) against *C. albicans*. The synthesized compounds have the same activity as the reference when the benzyl group was substituted with the EWG. Compounds **126(A3, B1, C2, C3, D3, E3, E4, G3, G4, H2 and I1)** displayed the highest antifungal activity against *Candida* spp. All compounds were tested for antioxidant and metal chelating assays, reducing power from CUPRAC, free radical scavenging ability by DPPH and ABTS assay and phosphomolybdenum assays. The chelating property and antioxidant activity was estimated via EDTA and Trolox. Among the synthesized compounds, most compounds showed similar antioxidant effects and cytotoxicity as the reference compounds.

### 3.8 Anticonvulsant Activity


Faizi and coworkers [149] synthesized new BZD derivatives and examined the compounds for biological evaluation. The novel compounds were synthesized by reaction of hydrazide, aldehydes and thioglycolic acid using anhydrous ZnCl<sub>2</sub> in dry toluene. The synthesized compounds consisted of the functional group which easily combined with benzodiazepine receptors and 4-thiazolidinone ring as a pharmacophore moiety. Here, the mechanism showed that, firstly, an aromatic nucleophilic substitution reaction occurred in 2,4-dichlorobenzoic acid with phenol to form 2,4-chloro-2-phenoxybenzoic acid, followed by esterification, and then combined with hydrazine hydrate to yield



**Fig. 10** Structure of the most anti-adipogenic compound **129** [3-benzyl-5-(4-{2-hydroxy-3-[(pyridin-2-ylmethyl)-amino]-propoxy}-benzylidene)-thiazolidine-2,4-dione]




**Fig. 11** Chemical structure of (*R*)-Se-phenyl thiazolidine-4-carboselenoate (Se-PTC)



4-chloro-2-phenoxybenzohydrazide. The products **127(a–j)** were synthesized by treatment of 4-chloro-2-phenoxybenzoic acid hydrazide with different benzaldehydes and were further refluxed with thioglycolic acid (Scheme 96). Compound **127i** displayed significant anticonvulsant effect in PTZ test and showed good hypnotic effect, whereas compounds **127a**, **127b**, **127e**, **127f**, **127h** and **127i** revealed good activity in the MES model. Flumazenil worked to antagonize the sedative-hypnotic effect of compounds which contain benzodiazepine. However, **127i** did not display any change in the anterograde memory and also did not show neurotoxicity. Some of the tested compounds exhibited antiepileptic effects by PTZ and MES models.

Nikalje and coworkers [150] reported the synthesis of novel N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives under MW conditions. The compounds **128(a–j)** were prepared by multistep synthesis. In the first step, benzoyl chloride reacted with glycine in aq. NaOH to form 2-benzamidoacetic acid, which showed esterification and gave ethyl 2-benzamido acetate. Ethyl 2-benzamido acetate and hydrazine hydrate were refluxed in ethanol to obtain (2-hydrazinyl-2-oxoethyl)benzamide, which was further refluxed with different heterocyclic and aromatic aldehydes using glacial acetic acid in ethanol to obtain Schiff bases. Compounds **128(a–j)** were prepared under MWI for 12–17 min by cyclization of the Schiff base and thioglycolic acid, using anhydrous ZnCl<sub>2</sub> and DMF (Scheme 97). The synthesis of final compounds was based on a four-point pharmacophoric HBD model, electron donor moiety (D), distal aryl domain (A) and distal hydrophilic-hydrophobic aryl ring (C) for validation using computational parameters like molecular docking, pharmacokinetic properties (ADME) and log P and for anticonvulsant evaluation, maximal electroshock seizure and subcutaneous pentylenetetrazole, and chemical testing in a mouse model. The neurotoxicity was evaluated by calculating minimal motor impairment via rotarod test. Compound **128h** showed highly potent and long-acting protection against a 30-mg/kg dose at 0.5-h and 4-h intervals, whereas compound **128f** also showed high potency only at a 0.5-h interval. But compound **128d** showed potent and long-acting inhibition against 100 mg/kg at both time intervals. Compounds **128a**, **128g** and **128h** displayed shielding of 100 mg/kg at a 0.5-h time interval in sc-PTZ screening. The SAR study manifested that the presence of small electron-donating polar groups at the phenyl ring and the presence of a heterocyclic ring (-indolyl) in the place of the aromatic ring exhibited good anticonvulsant effect. The docking studies concluded that all the newly synthesized compounds acted by inhibition voltage-gated ion channels (generally sodium channels).



**Scheme 98** Synthesis of 4-thiazolidinone derivatives **131(a-t)**





















### 3.9 Miscellaneous Activity



Sabbua and colleagues [151] synthesized a new amino alcohol and thiazolidinone hybrid, inspired by aegeline, and also evaluated their anti-adipogenic activity. Compounds (*Z*)-*N*-(3-(4-((2,4-dioxothiazolidin-5-ylidene)methyl) phenoxy)-2-hydroxypropyl)benzamides were produced from Knoevenagel condensation of *N*-(3-(4-formylphenoxy)-2-hydroxypropyl)benzamide with methanol and piperidine. Other thiazolidine-2,4-dione derivatives were prepared through ring-opening reaction of (*Z*)-3-benzyl-5-(4-(oxiran-2-ylmethoxy)benzylidene)thiazolidine-2,4-dione with substituted benzylamines and picolylamines, respectively, in isopropanol under different conditions. Among all the synthesized compounds, **129** was the potent inhibitor of adipocyte differentiation, which stopped adipogenesis and lipodosis in 3T3-L1 preadipocyte cells by blocking of the S-phase of the cell cycle, prevented mitotic clonal development and decreased two vital transcription factors, PPAR $\gamma$  and C/EBP $\alpha$ , and correlated genes like aP2 and FAS of adipocyte differentiation. The authors concluded that the final compounds effectively worked on obesity and related metabolic disorders (Fig. 10).

Sousa et al. [152] investigated Se-phenyl-thiazolidine-4-carboselenoate (**130**) (Se-PTC) as a protective agent against oxidative and behavioral stress in a mania model induced by ouabain (OUA), which is an extremely hazardous substance, in male rats (Fig. 11). The authors concluded that Se-PTC showed anti-manic-like action and protection against hyperlocomotion and brain oxidative stress in rats, prevented increased locomotor activity, and normalized the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase, while the LiCl (lithium chloride) blocked the increased crossing induced by OUA and also managed bipolar disorder (BD).

Rahim and coauthors [153] synthesized 4-thiazolidinone analogs and investigated them for urease inhibition. The final compounds were synthesized in two steps: initially, substituted carbonyl compounds were refluxed with thiosemicarbazide and HCl in EtOH, and Schiff bases were formed, which further reacted with chloroacetic acid and CH<sub>3</sub>COONa using glacial AcOH, to furnish 4-thiazolidinone derivatives **131(a-t)** (Scheme 98). All synthesized molecules gave moderate to excellent inhibition, with IC<sub>50</sub> values in the range of 1.73–69.65 as compared to standard

**Table 7** Different substituents of thiazolidine analogs **131(a–t)**

S.no.	R	R'	S.no.	R	R'
<b>a</b>	H		<b>k</b>	H	
<b>b</b>	H		<b>l</b>	H	
<b>c</b>	H		<b>m</b>	H	
<b>d</b>	H		<b>n</b>	H	
<b>e</b>	H		<b>o</b>	CH <sub>3</sub>	
<b>f</b>	H		<b>p</b>	H	
<b>g</b>	H		<b>q</b>	H	
<b>h</b>	H		<b>r</b>	H	
<b>i</b>	H		<b>s</b>	H	
<b>j</b>	H		<b>t</b>	H	



**Fig. 12** Structure of inhibitors CBTMT (**132**) and MBTMT (**133**)

thiourea. Among all newly synthesized compounds, **131(c, f, h, j, o, p, q, s and t)** showed excellent inhibition activity with IC<sub>50</sub> values of  $9.34 \pm 0.02$ ,  $14.62 \pm 0.03$ ,  $8.43 \pm 0.01$ ,  $7.3 \pm 0.04$ ,  $2.31 \pm 0.002$ ,  $5.75 \pm 0.003$ ,  $8.81 \pm 0.005$  and  $1.73 \pm 0.001$ ,

respectively. The pharmacological activity of compounds was affected by the steric effect, different substituents and their positions (Table 7).

Yadav et al. [154] investigated an efficient, less toxic synthesis of CBTMT and MBTMT and evaluated their corrosion inhibition activity on mild steel in 15% HCl sol. using potentiodynamic polarization, weight loss measurements and EIS techniques (Fig. 12). The concentration of inhibitor and temperature affected their efficiency of reaction: with increase in concentration, efficiency increased, but increased temperature decreased their efficiency. The weight loss measurement revealed that MBTMT (97.5%) showed higher efficiency than CBTMT (95.8%) at 303 K. This inhibition process was based mainly on adsorption, with both inhibitors obeying the Langmuir adsorption isotherm, and it was concluded that their inhibition depended on the covered surface area and number of active sites, i.e. N and S atoms. The higher value of  $\mu$  (dipole moment) and lower value of  $\Delta E$  (energy gap) enhanced compound inhibition efficiency.

## 4 Discussion

Green chemistry is a fascinating area in the field of sustainable synthesis. Green solvents and catalysts play a significant role in synthetic organic chemistry. Today's chemistry researchers need to explore new avenues of synthetic methodologies and biological applications of heterocyclic scaffolds. Though various developments have occurred in the synthetic and biological study of thiazolidine and its derivatives, there is a need for further development of the chemistry to enhance discoveries in this field. During the extensive review of the literature review on thiazolidine and its derivatives, several strengths and weaknesses were noted. For example, solvents used in the process of synthesis are hazardous to the environment, and therefore solvent-free synthesis has proven to be a boon for the environment and society, as it reduces waste and energy consumption. Solvents also serve as a heat transfer medium, and thus detailed study of their thermodynamics is required. A major drawback regarding the purification procedures (column chromatography) is that they require a large amount of solvents for purification, so extensive research is needed to avoid flaws. Ionic liquids are used as green solvents due to their recyclability, low volatility and so forth, but their high cost, safety issues and lack of generalization limit their use. In the recent scenario, crucial improvements in issues such as energy efficiency, by-product generation, impurity removal procedures, release of toxic products, whole life-cycle study and following common basic procedures with some modifications are necessary in the context of cost, population, environment, energy, health and resources. For industrial-level applications, synthesis methods could fulfill parameters including atom economy, environmental factor (e-factor), ecoscale, process profile, life-cycle analysis, environmental quotient and effective mass yield. Regarding pharmacological significance, thiazolidine-containing drugs show a variety of biological activity due to interactions such as hydrogen bonding, ion-dipole interaction, hydrophobic action,  $\pi$ - $\pi$  interaction, Van der Waal forces and bonding with various enzymes and pharmacophores.

Besides all these concerns, several drugs containing thiazolidine derivatives are banned due to their side effects, fluid retention properties and idiosyncratic hepatotoxicity, and several are associated with risk for bladder cancer, edema, liver failure and heart failure. Therefore, critical study is needed with special emphasis on SAR and the role of PPARs in molecular mechanisms and biological activity. A better understanding of the structure of ligands and receptors and their interaction needs to be achieved. Keeping all these facts in view, thiazolidine motifs will prove to be valuable candidates for designing more effective and potent drugs by reducing their side effects. This review article includes a detailed study of thiazolidine and its derivatives, and their varied synthesis and pharmaceutical applications, and will pave a better pathway for future directions and challenges.

## 5 Conclusion

This review article summarizes the major developments in the fabrication of the thiazolidine nucleus and its hybrids via molecular hybridization techniques that proceed through fusion of active motifs and pharmacophore units with advantages including dual action, change in selectivity profile, lower toxicity, and the design of new scaffolds in environmentally benign conditions such as microwave- and ultrasound-mediated synthesis, reusable catalysts, easy workup and solvent-free techniques with high atom economy. The application of MW-, nanoparticle- and ionic liquid-mediated synthesis in such processes has opened a new avenue for thiazolidine formation. It is likely that in the future, many more powerful and benign methodologies will emerge in this field. Furthermore, attention should be paid to modification and substitution in thiazolidine nuclei and also toward SAR and docking studies for improving the design strategies for drug targets. On a global scale, the opportunity in the field of thiazolidine is broad for synthetic and medical discovery, and this knowledge has been applied in the synthesis of multi-target hybrid drugs, which control diseases such as diabetes, cancer, multiple sclerosis and lupus. We trust that this review will serve as an update for researchers focused on the synthesis of thiazolidine derivatives and will encourage further growth in this field.

**Acknowledgements** Nusrat Sahiba is thankful to CSIR-HRDG for providing a junior research fellowship as financial support [09/172(0088)/2018-EMR-I]. The authors are grateful to the Department of Chemistry, M.L.S.U. Udaipur (Raj.), India, for providing necessary laboratory and library facilities. We would also like to express sincere thanks to the anonymous reviewers for their beneficial comments.

## Compliance with Ethical Standards

**Conflict of interest** The authors declare no conflict of interest, financial or otherwise.

## References

1. Guo L, Zhang D (2009) Cyclic poly( $\alpha$ -peptoids) and their block copolymers from N-heterocyclic carbene-mediated ring-opening polymerizations of N-substituted N-carboxylanhydrides. *J Am Chem Soc* 131:18072–18074
2. Butuc E, Gherasim GM (1984) Ordered heterocyclic copolymers. Polyamide-imides with S-triazine rings. *J Polym Sci* 22:503–507
3. Stead CV (1982) Halogenated heterocycles in reactive dyes. *Dyes Pigments* 3:161–171
4. Sniady A, Morreale MS, Wheeler KA, Dembinski R (2008) Room-temperature electrophilic 5-endo-dig chlorocyclization of alk-3-yn-1-ones with the use of pool sanitizer: synthesis of 3-chlorofurans and 5-chlorofuropyrimidine nucleosides. *Eur J Org Chem*. <https://doi.org/10.1002/ejoc.200800397>
5. Sarvary A, Maleki A (2014) A review of syntheses of 1,5-disubstituted tetrazole derivatives. *Mol Divers* 19:189–212
6. Shaabani A, Maleki A, Rezayan AH, Sarvary A (2011) Recent progress of isocyanide-based multi-component reactions in Iran. *Mol Divers* 15:41–68
7. Maleki A, Sarvary A (2015) Synthesis of tetrazoles via isocyanide-based reactions. *RSC Adv* 5:60938–60955
8. Zhang Q, Zhou H, Zhai S, Yan B (2010) Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities. *Curr Pharm Des* 16:1826–1842
9. Havrylyuk D, Zimenkovsky B, Vasylenko O, Lesyka R (2013) Synthesis and anticancer and antiviral activities of new 2-pyrazoline-substituted 4-thiazolidinones. *J Heterocycl Chem* 50:E55–E62
10. Osmaniye D, Levent S, Ardiç CM, Atlı Ö, Özkay Y, Kaplancıklı ZA (2017) Synthesis and anticancer activity of some novel benzothiazole-thiazolidine derivatives. *Phosphorus Sulfur Silicon Relat Elem* 193:249–256
11. El-Gaby MSA, Ismail ZH, Abdel-Gawad SM, Aly HM, Ghorab MM (2009) Synthesis of thiazolidine and thiophene derivatives for evaluation as anticancer agents. *Phosphorus Sulfur Silicon Relat Elem* 184:2645–2654
12. Agarwal S, Agarwal DK, Gautam N, Agarwal K, Gautam DC (2014) Synthesis and in vitro antimicrobial evaluation of benzothiazole incorporated thiazolidin-4-ones derivatives. *J Korean Chem Soc* 58:33–38
13. Sankar PS, Divya K, Padmaja A, Padmavathi V (2017) Synthesis and antimicrobial activity of azeletinone and thiazolidinone derivatives from azolyindolyl Schiff's bases. *Med Chem* 7:340–347
14. Deep A, Kumar P, Narasimhan B, Ramasamy K, Mani V, Mishra RK, Majeed ABA (2015) Synthesis, antimicrobial, anticancer evaluation of 2-(aryl)-4- thiazolidinone derivatives and their QSAR studies. *Curr Top Med Chem* 15:990–1002
15. Gouda MA, Abu-Hashem AA (2011) Synthesis, characterization, antioxidant and antitumor evaluation of some new thiazolidine and thiazolidinone derivatives. *Arch Pharm Chem Life Sci* 11:170–177
16. Nishida S, Maruoka H, Yoshimura Y, Goto T, Tomita R, Masumoto E, Okabe F, Yamagata K, Fujioka T (2012) Synthesis and biological activities of some new thiazolidine derivatives containing pyrazole ring system. *J Heterocycl Chem* 49:303–309
17. Datar PA, Aher SB (2016) Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents. *J Saudi Chem Soc* 20:S196–S201
18. Moreira DRM, Costa SPM, Hernandez MZ, Rabello MM, de Oliveria Filho GB, de Melo Cristiane ML, da Rocha LF, de Simone CA, Ferreira RS, Fradico JRB, Meira CS, Guimarães ET, Srivastava RM, Pereira VRA, Soares MBP, Leite ACL (2012) Structural investigation of anti-*Trypanosoma cruzi* 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice. *J Med Chem* 55:10918–10936
19. Zehetmeyer FK, Pereira da Silva MAM, Pereira KM, Berne MEA, Cunico W, Júnior JCC, Gouveia DP, da Silva Nascente P, de Oliveria Hübner S, Siqueira GM (2018) Ovicidal in vitro activity of 2-aryl-3-(2-morpholinoethyl)thiazolidin-4-ones and 2-aryl-3-(3-morpholinopropyl)thiazolidin-4-ones against *Fasciola hepatica* (Linnaeus, 1758). *Exp Parasitol* 192:60–64
20. Geronikaki AA, Lagunin AA, Hadjipavlou-Litina DI, Eleftheriou PT, Filimonov DA, Poroikov VV, Alam I, Saxena AK (2008) Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. *J Med Chem* 51:1601–1609

21. Ma L, Xie C, Ma Y, Liu J, Xiang M, Ye X, Zheng H, Chen Z, Xu Q, Chen T, Chen J, Yang J, Qiu N, Wang G, Liang X, Peng A, Yang S, Wei Y, Chen L (2011) Synthesis and biological evaluation of novel 5-benzylidene-thiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases. *J Med Chem* 54:2060–2068
22. Barros CD, Amato AA, de Oliveira TB, Iannini KBR, da Silva AL, da Silva TG, Leite ES, Hernandez MZ, de Lima MCA, Galdino SL, de Asis Rocha Neves F, da Rocha Pitta I (2010) Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPAR $\gamma$  ligands. *Bioorg Med Chem* 18:3805–3811
23. Chilamakuru NB, Shankaranath V, Rajasekhar KK, Singirisetty T (2013) Synthesis, characterisation and anti-tubercular activity of some new 3,5-disubstituted-2,4-thiazolidinediones. *Asian J Pharm Clin Res* 6:29–33
24. Siddiqui IR, Singh PK, Singh J, Singh J (2003) Synthesis and fungicidal activity of novel 4,4'-bis(2''-aryl-5''-methyl/unsubstituted-4''-oxo-thiazolidin-3''-yl) bibenzyl. *J Agric Food Chem* 51:7062–7065
25. Nitsche C, Schreier VN, Behnam MAM, Kumar A, Bartenschlager R, Klein CD (2013) Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture. *J Med Chem* 56:8389–8403
26. Romine JL, St. Laurent DR, Leet JE, Martin SW, Serrano-Wu MH, Yang F, Gao M, O'Boyle DR, Lemm JA, Sun JH, Nower PT, Huang X, Deshpande MS, Meanwell NA, Snyder LB (2011) Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes. *ACS Med Chem Lett* 2:224–229
27. Jiang S, Tala SR, Lu H, Abo-Dya NE, Avan I, Gyanda K, Lu L, Katritzky AR, Debnath AK (2011) Design, synthesis, and biological activity of novel 5-((arylfuran/1*H*-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. *J Med Chem* 54:572–579
28. Barreca ML, Balzarini J, Chimirri A, De Clercq E, De Luca L, Holtje HD, Holtje M, Monforte AM, Monforte P, Pannecouque C, Rao A, Zappala M (2002) Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. *J Med Chem* 45:5410–5413
29. Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E (2007) Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. *Bioorg Med Chem* 15:1725–1731
30. Janovec L, Sabolová D, Kožurková M, Paulíková H, Kristian P, Ungvarský J, Moravčíková E, Bajdichova M, Podhradsky D, Imrich J (2007) Synthesis, DNA interaction, and cytotoxic activity of a novel proflavine-dithiazolidinone pharmacophore. *Bioconjugate Chem* 18:93–100
31. Patrick DA, Gillespie JR, McQueen J, Hulverson MA, Ranade RM, Creason SA, Herbst ZM, Gelb MH, Buckner FS, Tidwell RR (2017) Urea derivatives of 2-aryl-benzothiazol-5-amines: a new class of potential drugs for human African trypanosomiasis. *J Med Chem* 60:957–971
32. Pavin NF, Donato F, Cibir FW, Jesse CR, Schneider PH, de Salles HD, Amaral Soares L, Alves D, Savegnago L (2011) Antinociceptive and anti-hypernociceptive effects of Se-phenyl thiazolidine-4-carboselenoate in mice. *Eur J Pharmacol* 668:169–176
33. Sirivolu VR, Vernekar SKV, Marchand C, Naumova A, Chergui A, Renaud A, Stephen AG, Chen F, Sham YY, Pommier Y, Wang Z (2012) 5-Arylidene-thioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I. *J Med Chem* 55:8671–8684
34. Liu Y, Jing F, Xu F, Xie Y, Shi F, Fang H, Li M, Xu W (2011) Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. *Bioorg Med Chem* 19:2342–2348
35. Ramazani Y, Levchenko EN, Heuvel LVD, Schepdael AV, Paul P, Ivanova EA, Pastore A, Hartman TM, Price NPJ (2017) Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. *Carbohydr Res* 439:9–15
36. Hosseinimehr SJ, Shafiee A, Mozdarani H, Akhlagpour S, Froughzadeh M (2002) Radioprotective effects of 2-imino-3-[(chromone-2-yl)carbonyl] thiazolidines against  $\gamma$ -irradiation in mice. *J Radiat Res* 43:293–300
37. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T (2010) 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. *J Med Chem* 53:4198–4211

38. Urbano M, Guerrero M, Velaparthy S, Crisp M, Chase P, Hodder P, Schaeffer MT, Brown S, Rosen H, Roberts E (2011) Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2*Z*,5*Z*)-5-((pyrrol-3-yl)methylene)-3-alkyl-2-(alkylimino)thiazolidin-4-one chemotype. *Bioorg Med Chem Lett* 21:6739–6745
39. Bi X, Pasunooti KK, Lescar J, Liu CF (2017) Thiazolidine-masked  $\alpha$ -oxo aldehyde functionality for peptide and protein modification. *Bioconjugate Chem* 28:325–329
40. Katayama H, Morisue S (2017) A novel ring opening reaction of peptide *N*-terminal thiazolidine with 2, 2'-dipyridyl disulfide (DPDS) efficient for protein chemical synthesis. *Tetrahedron* 73:3541–3547
41. Oh J, Patel J, Park HB, Crawford JM (2018)  $\beta$ -Lactam biotransformations activate innate immunity. *J Org Chem* 83:7173–7179
42. Chen H, Yin Q, Li C, Wang E, Gao F, Zhang X, Yin Z, Wei S, Li X, Meng M, Zhang P, Li N, Zhang J (2011) Synthesis of *C*-pseudonucleosides bearing thiazolidin-4-one as a novel potential immunostimulating agent. *ACS Med Chem Lett* 2:845–848
43. Liu J, Chan KKJ, Chan W (2016) Identification of protein thiazolidination as a novel molecular signature for oxidative stress and formaldehyde exposure. *Chem Res Toxicol* 29:1865–1871
44. Bivona LA, Giacalone F, Vaccaro L, Aprile C, Gruttaduria M (2015) Cross-linked thiazolidine network as support for palladium: a new catalyst for Suzuki and Heck reactions. *ChemCatChem* 7:2526–2533
45. Kozell V, McLaughlin M, Strappaveccia G, Santoro S, Bivona LA, Aprile C, Gruttaduria M, Vaccaro L (2016) Sustainable approach to waste-minimized Sonogashira cross-coupling reaction based on recoverable/reusable heterogeneous catalytic/base system and acetonitrile azeotrope. *ACS Sustain Chem Eng* 4:7209–7216
46. Bozdag-dündar O, Ertan R, Aboul-Enein HY, Kładna A, Kruk I (2011) Free radical scavenging abilities of flavonylthiazolidine-2,4-dione compounds. *Luminescence* 26:10–16
47. Bozdag-dündar O, Gürkan S, Aboul-Enein HY, Kruk I, Kładna A (2009) Scavenging of superoxide anion radical and hydroxyl radical by novel thiazolythiazolidine-2,4-dione compounds. *Luminescence* 24:194–201
48. De B, Adhikari I, Nandy A, Saha A, Goswami BB (2017) In silico modelling of thiazolidine derivatives with antioxidant potency: models quantify the degree of contribution of molecular fragments towards the free radical scavenging ability. *J Mol Struct* 1138:17–26
49. Ueda S, Terauchi H, Yano A, Matsumoto M, Kubo T, Kyoya Y, Suzuki K, Ido M, Kawasaki M (2004) 4,5-Dialkylsubstituted 2-imino-1,3-thiazolidine derivatives as potent inducible nitric oxide synthase inhibitors. *Bioorg Med Chem* 12:4101–4116
50. Xiao B, Tang A, Yang J, Wei Z, Zhou E (2017) P3HT-based photovoltaic cells with a high Voc of 1.22 V by using a benzotriazole-containing nonfullerene acceptor end-capped with thiazolidine-2,4-dione. *ACS Macro Lett* 6:410–414
51. Thyagarajan BS, Simon Nee Glowienka JA (1988) Novel synthesis of thiazolidine derivatives. *Synth Commun* 18:197–203
52. Maleki A, Ghassemi M, Firouzi-Haji R (2014) Green multicomponent synthesis of four different classes of six-membered *N*-containing and *O*-containing heterocycles catalyzed by an efficient chitosan-based magnetic bionanocomposite. *Pure Appl Chem*. <https://doi.org/10.1515/pac-2017-0702>
53. Maleki A (2013) One-pot multicomponent synthesis of diazepine derivatives using terminal alkynes in the presence of silica-supported superparamagnetic iron oxide nanoparticles. *Tetrahedron Lett* 54:2055–2059
54. Maleki A (2014) One-pot three-component synthesis of pyrido [2',1':2,3]imidazo[4,5-*c*]isoquinolines using Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>-OSO<sub>3</sub>H as an efficient heterogeneous nanocatalyst. *RSC Adv* 4:64169–64173
55. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK (2012) Recent developments and biological activities of thiazolidinone derivatives: a review. *Bioorg Med Chem* 20:3378–3395
56. Jain VS, Vora DK, Ramaa CS (2013) Thiazolidine-2,4-diones: progress towards multifarious applications. *Bioorg Med Chem* 21:1599–1620
57. Nanjan MJ, Mohammed M, Kumar BRP, Chandrasekar MJN (2018) Thiazolidinediones as antidiabetic agents: a critical review. *Bioorg Chem* 77:548–567
58. Shelke RN, Pansare DN, Pawar CD, Deshmukh AC, Pawar RP, Bembalkar SR (2017) Synthesis of 2-((substituted)-2-chloroquinolin-3-yl)-3-((substituted) phenyl) thiazolidin-4-one with  $\beta$ -cyclodextrin-SO<sub>3</sub>H catalyst under solvent-free condition. *J Chem* 6:24–33



59. Bhattacharyya A, Kavitha CV, Ghorai MK (2016) Stereospecific synthesis of 2-iminothiazolidines via domino ring-opening cyclization of activated aziridines with aryl- and alkyl isothiocyanates. *J Org Chem* 81:6433–6443
60. Domling A, Wang W, Wang K (2012) Chemistry and biology of multicomponent reactions. *Chem Rev* 112:3083–3135
61. Biggs-Houck JE, You-nai A, Shaw JT (2010) Recent advances in multicomponent reactions for diversity-oriented synthesis. *Curr Opin Chem Biol* 14:371–382
62. da Silva DS, da Silva CEH, Soares MSP, Azambuja JH, da Rosa Carvalho T, Zimmer GC, Frizzo CP, Braganhol E, Spanevello RM, Cunico W (2016) Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4(methylsulfonyl)benzaldehyde: synthesis, antiangioma activity and cytotoxicity. *Eur J Med Chem* 124:574–582
63. Rahim F, Taha M, Ullah H, Wadood A, Selvaraj M, Rab A, Sajid M, Shah SAA, Uddin N, Gollapalli M (2019) Synthesis of new arylhydrazide bearing Schiff bases/thiazolidinone:  $\alpha$ -amylase, urease activities and their molecular docking studies. *Bioorg Chem*. <https://doi.org/10.1016/j.bioorg.2019.103112>
64. Kaboudin B, Shiran JA (2018) Novel one-pot four-component condensation cyclization reactions for the synthesis of thiazolidine-4-one and 3*H*-thiazoles. *J Sulfur Chem*. <https://doi.org/10.1080/17415993.2018.1497168>
65. Bayat M, Hosseini FS, Nasri S (2018) An efficient one-pot synthesis of tetrahydrothiazolo[3,2-*a*]quinolin-6-one derivatives. *J Sulfur Chem* 39:99–111
66. Santeusano S, Majer R, Perrulli FR, de Crescentini L, Favi G, Giorgi G, Mantellini F (2017) Divergent approach to thiazolylidene derivatives: a perspective on the synthesis of a heterocyclic skeleton from  $\beta$ -amidothioamides reactivity. *J Org Chem* 82:9773–9778
67. Revelant G, Huber-Villaumje S, Dunand S, Kirsch G, Schohn H, Hesse S (2015) Synthesis and biological evaluation of novel 2-heteroarylrimino-1,3-thiazolidin-4-ones as potential anti-tumor agents. *Eur J Med Chem* 94:102–112
68. Yahiaoui S, Moliterni A, Corriero N, Cuocci C, Toubal K, Chouaih A, Djafri A, Hamzaoui F (2018) 2-thioxo-3*N*-(2-methoxyphenyl)-5[4'-methyl-3'*N*-(2'-methoxyphenyl) thiazol-2'(3*H*)-ylidene] thiazolidin-4-one: synthesis, characterization, X-ray single crystal structure investigation and quantum chemical calculations. *J Mol Struct*. <https://doi.org/10.1016/j.molstruc.2018.09.052>
69. Hassan RM, Abd-Allah WH, Salman AM, Abdel-Sattar El-Azzouny A, Aboul-Enein MN (2019) Design, synthesis and anticancer evaluation of novel 1,3-benzodioxoles and 1,4-benzodioxines. *Eur J Pharm Sci* 139:105045
70. Maleki A, Jafari AA, Yousefi S (2017) Green cellulose-based nanocomposite catalyst: design and facile performance in aqueous synthesis of pyranopyrimidines and pyrazolopyranopyrimidines. *Carbohydr Polym* 175:409–416
71. Gandhi D, Agarwal S (2018) MgO NPs catalyzed eco-friendly reaction: a highly effective and green approach for the multicomponent one-pot synthesis of polysubstituted pyridines using 2-aminobenzothiazole. *J Heterocycl Chem* 55:2977–2984
72. Maleki A, Movahed H, Ravaghi P (2017) Magnetic cellulose/Ag as a novel eco-friendly nanobiocomposite to catalyze synthesis of chromene-linked nicotinonitriles. *Carbohydr Polym* 156:259–267
73. Maleki A, Eskandarpour V, Rahimi J, Hamidi N (2018) Cellulose matrix embedded copper decorated magnetic bionanocomposite as a green catalyst in the synthesis of dihydropyridines and polyhydroquinolines. *Carbohydr Polym* 208:251–260
74. Maleki A, Firouzi-Haji R, Hajizadeh Z (2017) Magnetic guanidinylated chitosan nanobiocomposite: a green catalyst for the synthesis of 1,4-dihydropyridines. *Int J Biol Macromol* 116:320–326
75. Maleki A, Firouzi-Haji R (2018) L-Proline functionalized magnetic nanoparticles: a novel magnetically reusable nanocatalyst for one-pot synthesis of 2,4,6-triarylpyridines. *Sci Rep* 8:17303
76. Maleki A, Hajizadeh Z, Sharifi V, Emdadi Z (2019) A green, porous and eco-friendly magnetic geopolymer adsorbent for heavy metals removal from aqueous solutions. *J Clean Prod*. <https://doi.org/10.1016/j.jclepro.2019.01.084>
77. Safaei-Ghomi J, Nazemzadeh SH, Shahbazi-Alavi H (2017) Nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub> as a reusable and robust catalyst for the synthesis of bis-thiazolidinones by a multicomponent reaction of aldehydes, ethylenediamine and thioglycolic acid. *J Sulfur Chem* 38:195–205
78. Safaei-Ghomi J, Navvab M, Shahbazi-Alavi H (2016) CoFe<sub>2</sub>O<sub>4</sub>@SiO<sub>2</sub>/PrNH<sub>2</sub> nanoparticles as highly efficient and magnetically recoverable catalyst for the synthesis of 1,3-thiazolidin-4-ones. *J Sulfur Chem* 37:601–612

79. Sadeghzadeh SM, Daneshfar F (2014) Ionic liquid immobilized on FeNi<sub>3</sub> as catalysts for efficient, green, and one-pot synthesis of 1,3-thiazolidin-4-one. *J Mol Liq* 199:440–444
80. Azgomi N, Mokhtary M (2015) Nano-Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> supported ionic liquid as an efficient catalyst for the synthesis of 1,3-thiazolidin-4-ones under solvent-free conditions. *J Mol Catal A Chem* 398:58–64
81. Subhedar DD, Shaikh MH, Arkile MA, Yeware A, Sarkar D, Shingate BB (2016) Facile synthesis of 1,3-thiazolidin-4-ones as antitubercular agents. *Bioorg Med Chem Lett* 26:1704–1708
82. Chen CY, Barve IJ, Sun CM (2016) One-pot three-component synthesis of 2-imino-1,3-thiazolines on soluble ionic liquid support. *ACS Combin Sci* 18:638–643
83. Malla AM, Parveen M, Ahmad F, Azaz S, Alam M (2015) [Et<sub>3</sub>NH][HSO<sub>4</sub>]-catalyzed eco-friendly and expeditious synthesis of thiazolidine and oxazolidine derivatives. *RSC Adv* 5:19552–19569
84. Sadeghzadeh SM, Malekzadeh M (2015) Synthesis of 1,3-thiazolidin-4-one using ionic liquid immobilized onto Fe<sub>3</sub>O<sub>4</sub>/SiO<sub>2</sub>/Salen/Mn. *J Mol Liq* 202:46–51
85. Yedage DB, Patil DV (2018) Environmentally benign deep eutectic solvent for synthesis of 1,3-thiazolidin-4-ones. *Chem Select* 3:3611–3614
86. Dahiya A, Ali W, Patel BK (2018) Catalyst and solvent free domino ring opening cyclization: a greener and atom economic route to 2-iminothiazolidines. *ACS Sustain Chem Eng* 6:4272–4281
87. Mahmoodi NO, Mohammadgholipour S, Pirbasti FG (2017) Microwave-assisted one-pot three-component synthesis of thiazolidinones using KSF@Ni as an efficient heterogeneous catalyst. *J Sulfur Chem* 38:668–678
88. Sangeetha P, Sankar C, Tharini K (2019) New thiazolidinone substituted 2,6-diarylpiperid in-4-one: synthesis, crystal structure, spectral characterization, binding mode with calf thymus DNA. *J Mol Struct* 1198:126899
89. Maleki A (2017) Green oxidation protocol: selective conversions of alcohols and alkenes to aldehydes, ketones and epoxides by using a new multiwall carbon nanotube-based hybrid nanocatalyst via ultrasound irradiation. *Ultrason Sonochem* 40:460–464
90. Safaei-Ghomi J, Navvab M, Shabazi-Alavi H (2015) One-pot sonochemical synthesis of 1,3-thiazolidin-4-ones using nano-CdZr<sub>4</sub>(PO<sub>4</sub>)<sub>6</sub> as a robust heterogeneous catalyst. *Ultrason Sonochem* 31:102–104
91. Shaabani A, Hooshmand SE (2017) Diversity-oriented catalyst-free synthesis of pseudopeptides containing rhodanine scaffolds via a one-pot sequential isocyanide-based six-component reactions in water using ultrasound irradiation. *Ultrason Sonochem*. <https://doi.org/10.1016/j.ultsonch.2017.06.030>
92. Salehitabar L, Yavari I (2017) A synthesis of functionalized 2,5-diiminothiazolidines from Nef-isocyanide adduct and 1-alkyl-3-arylthioureas. *Phosphorus Sulfur Silicon Relat Elem* 192:1195–1200
93. Halimehiani AZ, Nosood YL (2017) Synthesis of N, S-heterocycles and dithiocarbamates by the reaction of dithiocarbamic acids and S-alkyl dithiocarbamates with nitroepoxides. *Org Lett* 19:6748–6751
94. Aly AA, Ibrahim MAA, Shehata EM, Hassan AAM, Brown AB (2018) Prospective new amidinothiazoles as leukotriene B<sub>4</sub> inhibitors. *J Mol Struct*. <https://doi.org/10.1016/j.molstruc.2018.07.085>
95. Ebrahimi S (2016) One-pot synthesis of 1,3-thiazolidin-4-one using ammonium persulfate as catalyst. *J Sulfur Chem* 37:587–592
96. Wu SL, Gao X (2018) Copper-catalyzed aerobic oxidative reaction of C<sub>60</sub> with aliphatic primary amines and CS<sub>2</sub>. *J Org Chem* 83:2125–2130
97. Shehzadi SA, Khan I, Saeed A, Larik FA, Channar PA, Hassan M, Raza H, Abbas Q, Seo SY (2019) One-pot four-component synthesis of thiazolidin-2-imines using CuI/ZnII dual catalysis: a new class of acetylcholinesterase inhibitors. *Bioorg Chem* 84:518–528
98. Robati M, Ghazanfari D, Islami MR, Saidi K (2017) Synthesis of new 1, 8-dioxo-octahydroxanthene derivatives containing 4-thiazolidinone moiety. *Iran J Chem Chem Eng*, p 36
99. Kandile NG, Mohamed MI, Ismaeel HM (2017) Synthesis of new Schiff bases bearing 1,2,4-triazole, thiazolidine and chloroazetididine moieties and their pharmacological evaluation. *J Enzym Inhib Med Chem* 32:119–129
100. Cihan-Üstündag G, Gürsoy E, Naesens L, Ulusoy-Güzeldemirci N, Çapan G (2016) Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones. *Bioorg Med Chem* 24:240–246
101. Thakare MP, Kumar P, Kumar N, Pandey SK (2014) Silica gel promoted environment-friendly synthesis of 2,3-disubstituted 4-thiazolidinones. *Tetrahedron Lett* 55:2463–2466

102. Abdel Hafez NA, Elsayed MA, El-Shahawi M, Awad GEA, Ali KA (2018) Synthesis and antimicrobial activity of new thiazolidine-based heterocycles as rhodanine analogues. *J Heterocycl Chem* 55:685–691
103. Singh RP, Aziz MN, Gout D, Fayad W, ElManawaty MA, Lovely CJ (2019) Novel thiazolidines: synthesis, antiproliferative properties and 2D-QSAR studies. *Bioorg Med Chem*. <https://doi.org/10.1016/j.bmc.2019.115047>
104. Obydenov KL, Khamidullina LA, Galushchinskiy AN, Shatunova SA, Kosterina MF, Kalinina TA, Fan Z, Glukhareva TV, Morzherin YY (2018) Discovery of methyl (5Z)-[2-(2,4,5-trioxopyrrolidin-3-ylidene)-4-oxo-1,3-thiazolidin-5-ylidene]acetates as antifungal agents against potato diseases. *J Agric Food Chem* 66:6239–6245
105. Trotsko N, Kosikowska U, Paneth A, Wujec M, Malm A (2018) Synthesis and antibacterial activity of new (2,4-dioxothiazolidin-5-yl)ylidene)acetic acid derivatives with thiazolidine-2,4-dione, rhodamine and 2-thiohydantoin moieties. *Saudi Pharm J* 26:568–577
106. Trotsko N, Kosikowska U, Paneth A, Plech T, Malm A, Wujec M (2018) Synthesis and antibacterial activity of new thiazolidine-2,4-dione-based chlorophenyl thiosemicarbazone hybrids. *Molecules* 23:1023
107. Xiang X, Tao H, Jiang S, Zhang LH, Cui ZN (2018) Synthesis and bioactivity of thiazolidin-2-cyanamide derivatives against type III secretion system of *Xanthomonas oryzae* on rice. *Pestic Biochem Phys* 149:89–97
108. Abdel-Galil E, Moawad EB, El-Mekabaty A, Said GE (2018) Synthesis, characterization and antibacterial activity of some new thiazole and thiazolidinone derivatives containing phenyl benzoate moiety. *Synth Commun* 149:2083–2092
109. Barakat A, Soliman SM, Al-Majid AM, Ali M, Islam MS, Elshaiher YAMM, Ghabbour HA (2018) New spiro-oxindole constructed with pyrrolidine/thioxothiazolidin-4-one derivatives: regioselective synthesis, x-ray crystal structures, Hirshfeld surface analysis, DFT, docking and antimicrobial studies. *J Mol Struct* 1152:101–114
110. Abdelmajeid A, Amine MS, Hassan RA (2017) Fatty acids in heterocyclic synthesis. Part XVII: synthesis of non-ionic surfactants containing piperidine, piperazine, imidazole based on thiazadiazole and microbiological activities evaluation. *Int J Org Chem* 7:346–368
111. Trotsko N, Przekora A, Zalewska J, Ginalska G, Paneth A, Wujec M (2018) Synthesis and in vitro antiproliferative and antibacterial activity of new thiazolidine-2,4-dione derivatives. *J Enzym Inhib Med Chem* 33:17–24
112. Pânzariu AT, Apotrosoaei M, Vasincu IM, Drăgan M, Constantin S, Buron F, Routier S, Profire L, Tuchilus C (2016) Synthesis and biological evaluation of new 1,3-thiazolidine-4-one derivatives of nitro-l-arginine methyl ester. *Chem Cent J* 10:6
113. Khan FAK, Jadhav KS, Patil RH, Shinde DB, Arote RB, Sangshetti JN (2016) Biphenyl tetrazole-thiazolidinediones as novel bacterial peptide deformylase inhibitors: synthesis, biological evaluations and molecular docking study. *Biomed Pharmacother* 83:1146–1153
114. Gilani SJ, Nagarajan K, Dixit SP, Taleuzzaman M, Khan SA (2016) Benzothiazole incorporated thiazolidin-4-ones and azetid-2-ones derivatives: synthesis and in vitro antimicrobial evaluation. *Arab J Chem* 9:S1523–S1531
115. Nastasă CM, Duma M, Pîrnău A, Vlase L, Tiperciuc B, Oniga O (2016) Development of new 5-(chromene-3-yl) methylene-2,4-thiazolidinediones as antimicrobial agents. *Clujul Med* 89:122–127
116. De Monte C, Carradori S, Bizzarri B, Bolasco A, Caprara F, Mollica A, Rivanera D, Mari E, Zicari A, Akdemir A, Secci D (2016) Anti-candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivative. *Eur J Med Chem* 107:82–96
117. Pansare DN, Mulla NA, Pawar CD, Shende VR, Shinde DB (2017) One pot three components microwave assisted and conventional synthesis of new 3-(4-chloro-2-hydroxyphenyl)-2-(substituted) thiazolidin-4-one as antimicrobial agent. *Bioorg Med Chem Lett* 24:3569–3573
118. Nechak R, Bouzroua SA, Benmalek Y, Salhi L, Martini SP, Morizur V, Dunach E, Kolli BN (2015) Synthesis and antimicrobial activity evaluation of novel 4-thiazolidinones containing a pyrone moiety. *Synth Commun* 45:262–272
119. Kunzler A, Neuenfeldt PD, des Neves AM, Pereira CMP, Marques GH, Nascente PS, Fernandes MHV, Hübner SO, Cunico W (2013) Synthesis, antifungal and cytotoxic activities of 2-aryl-3-((piperidin-1-yl)ethyl)thiazolidinones. *Eur J Med Chem* 64:74–80
120. Popiołeka Ł, Piątkowska-Chmiel I, Gawrońska-Grzywacz M, Biernasiuk A, Izdebskab M, Herbet M, Sysa M, Malm A, Dudka J, Wujec M (2018) New hydrazide-hydrazones and

- 1,3-thiazolidin-4-ones with 3-hydroxy-2-naphthoic moiety: synthesis, in vitro and in vivo studies. *Biomed Pharmacother* 103:1337–1347
121. Yakaiah S, Kumar PSV, Rani PB, Prasad KD, Aparna P (2018) Design, synthesis and biological evaluation of novel pyrazolooxothiazolidine derivatives as antiproliferative agents against human lung cancer cell line A549. *Bioorg Med Chem Lett* 28:630–636
  122. MdoD Rodrigues, Santiago Priscila BGS, Marques KMR, Pereira VRA, de Castro Maria CAB, Cantalice JCLL, da Silva TG, Adam ML, do Nascimento SC, de Albuquerque JFC, Militao GCG (2018) Selective cytotoxic and genotoxic activities of 5-(2-bromo-5-methoxybenzylidene)-thiazolidine-2,4-dione against NCI-H292 human lung carcinoma cells. *Pharm Rep* 70:446–454
  123. Ansari F, Idrees D, Hassan I, Ahmad K, Avcilla F, Azam A (2018) Design, synthesis and biological evaluation of novel pyridine-thiazolidinone derivatives as anticancer agents: targeting human carbonic anhydrase IX. *Eur J Med Chem* 144:544–556
  124. Asati V, Bharti SK (2018) Design, synthesis and molecular modeling studies of novel thiazolidine-2,4-dione derivatives as potential anti-cancer agents. *J Mol Struct* 1154:406–417
  125. Li R, Ning X, Zhou S, Lin Z, Wu X, Chen H, Bai X, Wang X, Ge Z, Li R, Yin Y (2017) Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators. *Eur J Med Chem* 143:48–65
  126. Kulabaş N, Özakpınar ÖB, Özsvacı D, Leyssen P, Neyts J, Küçükgüzel İ (2017) Synthesis, characterization and biological evaluation of thioureas, acylthioureas and 4-thiazolidinones as anticancer and antiviral agents. *J Res Pharm* 21:371–384
  127. Bataille CJR, Brennan MB, Byrne S, Davies SG, Durbin M, Fedorov O, Huber KVM, Jones AM, Knapp S, Liu G, Nadali A, Quevedo CE, Russell AJ, Walker RG, Westwood R, Wynne GM (2017) Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family. *Bioorg Med Chem* 25:2657–2665
  128. Sharma P, Reddy TS, Thummuri D, Senwar KR, Kumar NP, Naidu VGM, Bhargava SK, Shankaraiyah N (2016) Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents. *Eur J Med Chem* 124:608–621
  129. Kumar KSS, Hanumappa A, Vetrivel M, Hegde M, Girish YR, Byregowda TR, Rao S, Raghavan SC, Rangappa KS (2015) Antiproliferative and tumor inhibitory studies of 2,3 disubstituted 4-thiazolidinone derivatives. *Bioorg Med Chem Lett* 25:3616–3620
  130. Anh HLT, Cuc NT, Tai BH, Yen PH, Nhiem NX, Thao DT, Nam NH, Minh CV, Kiem PV, Kim YH (2015) Synthesis of chromonylthiazolidines and their cytotoxicity to human cancer cell lines. *Molecules* 20:1151–1160
  131. Kumar KS, Reddy BM, Babu VH (2014) Synthesis of some novel 2,4-thiazolidinedione incorporated pyrazole derivatives as anti-cancer agents. *Int J Pharm Pharm Sci* 6:831–834
  132. Akshaya TT, Arunlal VB, Babu G, Biju CR (2014) Synthesis, characterisation and in vitro anticancer activity of thiazolidine-2,4-dione derivatives. *J Drug Discov Ther* 2:42–47
  133. Yeh TK, Kuo CC, Lee YZ, Ke YY, Chu KF, Hsu HY, Chang HY, Liu YW, Song JS, Yang CW, Lin LM, Sun M, Wu SH, Kuo PC, Shih C, Chen CT, Tsou LK, Lee SJ (2017) Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors. *J Med Chem* 60:5599–5612
  134. Ashour HMA, El-Ashmawy IM, Bayad AE (2016) Synthesis and pharmacological evaluation of new pyrazolyl benzenesulfonamides linked to polysubstituted pyrazoles and thiazolidinones as anti-inflammatory and analgesic agents. *Monatsh Chem* 147:605–618
  135. Carzaniga L, Amari G, Rizzi A, Capaldi C, De Fanti R, Ghidini E, Villetti G, Carnini C, Moretto N, Facchinetti F, Caruso P, Marchini G, Battipaglia L, Patacchini R, Cenacchi V, Volta R, Amadei F, Pappani A, Capacchi S, Bagnacani V, Delcanale M, Puccini P, Catinella S, Civelli M, Armani E (2017) Discovery and optimization of thiazolidinyl and pyrrolidinyl derivatives as inhaled PDE4 inhibitors for respiratory diseases. *J Med Chem* 60:10026–10046
  136. Maccari R, Vitale RM, Ottanà R, Rocchiccioli M, Marrazzo A, Cardile V, Graziano ACE, Amodeo P, Mura U, Corso AD (2014) Structure activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents. *Eur J Med Chem* 81:1–14
  137. Oderinlo OO, Tukulula M, Isaacs M, Hoppe HC, Taylor D, Smith VJ, Khanye SD (2018) New thiazolidine-2,4-dione derivatives combined with organometallic ferrocene: Synthesis, structure and antiparasitic activity. *Appl Organomet Chem*. <https://doi.org/10.1002/aoc.4385>
  138. Jain S, Kumar A, Saini D (2018) Novel arylidene derivatives of quinoline based thiazolidinones: synthesis, in vitro, in vivo and in silico study as antimalarials. *Exp Parasitol* 185:107–114

139. Hidaka K, Kimura T, Sankaranarayanan R, Wang J, McDaniel KF, Kempf DJ, Kameoka M, Adachi M, Kuroki R, Nguyen JT, Hayashi Y, Kiso Y (2018) Identification of highly potent human immunodeficiency virus type-1 protease inhibitors against lopinavir and darunavir resistant viruses from allophenylnorstatine-based peptidomimetics with P2 tetrahydrofuranylglycine. *J Med Chem* 61:5138–5153
140. Wang GC, Peng YP, Xie ZZ, Wang J, Chen M (2017) Synthesis,  $\alpha$ -glucosidase inhibition and molecular docking studies of novel thiazolidine-2,4-dione or rhodanine derivatives. *Med Chem Commun* 8:1477–1484
141. Chhajed SS, Chaskar S, Kshirsagar SK, Haldar GMA, Mahapatra DK (2017) Rational design and synthesis of some PPAR- $\gamma$  agonists: substituted benzylideneaminobenzylidene- thiazolidine-2,4-diones. *Comput Biol Chem* 67:260–265
142. Kumar P, Duhan M, Kadyan K, Sindhu J, Kumar S, Sharma H (2017) Synthesis of novel inhibitors of  $\alpha$ -amylase based on thiazolidine-4-one skeleton containing pyrazole moiety and their configurational studies. *Med Chem Commun* 8:1468–1476
143. Patel KD, Patel CN, Patel GM (2016) Microwave assisted synthesis and antidiabetic activity of novel 5-[4-(substituted) benzylidene]thiazolidine-2,4-dione. *Med Chem* 6:647–651
144. Badiger NP, Shashidhar N, Vaidya PN (2015) Synthesis of novel 5-([2-(4-fluorobenzyl)-6-arylimidazo[2,1-*b*] [1,3,4]thiadiazol-5-yl]methylene)thiazolidine-2,4-diones as potent antidiabetic agents. *Int J Sci Eng Appl* 4:2319–7560
145. Mahapatra MK, Kumar R, Kumar M (2017) Synthesis, biological evaluation and in silico studies of 5-(3-methoxybenzylidene)thiazolidine-2,4-dione analogues as PTP1B inhibitors. *Bioorg Chem* 71:1–9
146. Alemán-González-Duhart D, Tamay-Cach F, Correa-Basurto J, Padilla-Martínez, Álvarez-Almazán S, Mendieta-Wejebe JE (2017) In silico design, chemical synthesis and toxicological evaluation of 1,3-thiazolidine-2,4-dione derivatives as PPAR $\gamma$  agonists. *Regul Toxicol Pharmacol* 86:25–32
147. Constantin S, Lupascu FG, Apotrosoaei M, Vasincu IM, Lupascu D, Buron F, Routier S, Profire L (2017) Synthesis and biological evaluation of the new 1,3-dimethylxanthine derivatives with thiazolidine-4-one scaffold. *Chem Cent J* 11:12
148. Secci D, Carradori S, Bizzarri B, Chimenti P, de Monte C, Mollica A, Rivanera D, Zicari A, Mari E, Zengin G, Aktumsek A (2016) Novel 1,3-thiazolidin-4-one derivatives as promising anti-*Candida* agents endowed with anti-oxidant and chelating properties. *Eur J Med Chem* 117:144–156
149. Faizi M, Jahani R, Ebadi SA, Tabatabai SA, Rezaee E, Lotfaliei M, Amini M, Almasirad A (2017) Novel 4-thiazolidinone derivatives as agonists of benzodiazepine receptors: design, synthesis and pharmacological evaluation. *EXCLI J* 16:52–62
150. Nikalje APG, Shaikh AN, Shaikh SI, Khan FAK, Sangshetti JN, Shind DB (2014) Microwave assisted synthesis and docking study of *N*-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino) ethyl)benzamide derivatives as anticonvulsant agents. *Bioorg Med Chem Lett* 21:444–448
151. Sabbua S, Srivastava A, Yadav P, Varshney S, Choudhary R, Balaramnavar VM, Tadigoppulaa N, Gaikwad AN (2018) Aegeline inspired synthesis of novel amino alcohol and thiazolidinedione hybrids with antiadipogenic activity in 3T3-L1 cells. *Eur J Med Chem* 143:780–791
152. Sousa FSS, Seus N, Alves D, Salles HD, Schneider PH, Savegnago L (2017) Evaluation of *Se*-phenyl-thiazolidine-4-carboselenoate protective activity against oxidative and behavioral stress in the maniac model induced by ouabain in male rats. *Neurosci Lett* 651:182–187
153. Rahim F, Zaman K, Ullah H, Taha M, Wadood A, Javed MT, Rehman W, Ashraf M, Uddin R, Uddin I, Asghar H, Khan AA, Khan MK (2015) Synthesis of 4-thiazolidinone analogs as potent in vitro anti-urease agents. *Bioorg Chem* 63:123–131
154. Yadav M, Kumar S, Kumari N, Bahadur I, Ebenso EE (2015) Experimental and theoretical studies on corrosion inhibition effect of synthesized benzothiazole derivatives on mild steel in 15% HCl solution. *Int J Electrochem Sci* 10:602–624
155. Alizadeh A, Rostamnia S, Zohreh N, Hosseinpour R (2009) A simple and effective approach to the synthesis of rhodanine derivatives via three-component reactions in water. *Tetrahedron Lett* 50:1533–1535
156. Attanasi OA, De Crescentini L, Favi G, Filippone P, Giorgi G, Mantellini F, Moscatelli G, Behalo MS (2009) An efficient one-pot, three-component synthesis of 5-hydrazinoalkylidene rhodanines from 1,2-diaza-1,3-dienes. *Org Lett* 11:2265–2268

157. Attanasi OA, Bartoccini S, Favi G, Giorgi G, Perrulli FR, Santeusano S (2012) Powerful approach to heterocyclic skeletal diversity by sequential three-component reaction of amines, isothiocyanates, and 1,2-diaza-1,3-dienes. *J Org Chem* 77:1161–1167
158. Dalmal T, Appalanaidu K, Kosurkar UB, Babu NJ, Kumbhare RM (2014) One-pot synthesis of 2-imino-4-(trifluoromethyl)thiazolidin-4-ol derivatives in a three-component reaction: application to structurally diverse scaffolds of biological interest through subsequent reactions. *Eur J Org Chem*. <https://doi.org/10.1002/ejoc.201301710>
159. Gan SF, Wan JP, Pan YJ, Sun CR (2010) Water-mediated multicomponent reaction: a facile and efficient synthesis of multisubstituted thiazolidine-2-thiones. *Synlett* 6:0973–0975
160. Kasmi-Mir S, Djafri A, Paquin L, Hamelin J, Rahmouni M (2006) One-pot synthesis of 5-arylidene-2-imino-4-thiazolidinones under microwave irradiation. *Molecules* 11:597–602
161. Schlüter T, Frerichs N, Schmidtman M, Martens J (2018) Consecutive multicomponent reactions: synthesis of 3-Acyl-4-alkynyl-substituted 1,3-thiazolidines. *Synthesis* 50:1123–1132
162. Dandia A, Singh R, Bhaskarana S, Samant SD (2011) Versatile three component procedure for combinatorial synthesis of biologically relevant scaffold spiro[indole-thiazolidinones] under aqueous conditions. *Green Chem* 13:1852–1859

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.